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Abstract 
 Nonribosomal peptides are an important class of natural products including the 
life-saving antibiotics penicillin and vancomycin and the deadly microcystins and 
cereulide.  This important category of natural products is thus a focus of many research 
labs around the world, including the Kelleher lab.  These often complex peptides are 
assembled by large enzymes having multiple active sites for activation, peptide bond 
formation as well as chemical tailoring.  The peptides are assembled on nonribosomal 
peptide synthetase (NRPS) assembly lines covalently tethered to the synthetases 
throughout biosynthesis.  Mass spectrometry is an especially well suited tool for 
analyzing both the products of NRPS pathways and the machinery that produces them.  A 
review of NRPS enzymology and contemporary mass spectrometric methods for their 
analysis is given in Chapter 1.  The work described in Chapter 2 for the first time brings 
to bear the power of mass spectrometry and directed evolution against the challenge of 
reengineering NRPSs.  A collaborative effort between members of the Kelleher lab that 
led to the development of a natural product discovery platform based upon proteomic 
analysis is described in Chapter 3.  The first discovery, sequencing and characterization 
of a novel NRPS biosynthetic gene cluster using this new proteomics based platform in 
the Kelleher lab is described in Chapter 4.  In summary, this thesis is founded on and 
extends upon the pioneering work of in vitro characterization of NRPSs performed in the 
Kelleher lab over the last decade and paves the way for an explosion of future discoveries 
using these and yet to be developed techniques.   
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CHAPTER 1 
INTRODUCTION 
 
The information and contents of this chapter were taken from the following article with 
permission from the publisher: Bradley S. Evans, Sarah J. Robinson, Neil L. Kelleher 
(2010). “Surveys of non-ribosomal peptide and polyketide assembly lines in fungi and 
prospects for their analysis in vitro and in vivo.” Fungal Genetics and Biology, 
doi:10.1016/j.fgb.2010.06.012. 
 
1.1 Background 
The sustained examination of medicinally relevant natural products and their 
biosyntheses is driven by the need for new medicines that will selectively inhibit targets 
implicated in human disease.  Drug discovery and synthesis are often inspired by new 
molecular scaffolds discovered in nature that can be used to probe and provide new 
information about biological targets.  Along with facile genome sequencing, such tools 
promise to increase the rate at which we can access and understand the ultra-large genes 
involved in production of non-ribosomal peptides and polyketides.  
Biosynthetic products span from essential primary metabolites such as fatty acids 
that make up the cell membrane to polyketides (PKs) and nonribosomal peptides (NRPs) 
that constitute pigments, antibiotics and siderophores.  An often exploited mechanism of 
natural product genesis is thiotemplate biosynthesis, which allows for indirect encoding 
of ketide and peptide metabolite biosynthesis by a protein template. Thiotemplating refers 
to the covalent tethering of intermediates to a unique cofactor, 4’-phosphopantetheine, 
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through a labile thioester bond.  These tethered intermediates are arranged along an 
assembly line of enzymes that are usually a multi-active site, mega-enzyme (type I), a 
series of interacting enzymes (type II), or (for polyketide synthases (PKSs)) a single 
active site enzyme that acts repeatedly to form the final product (type III).  The assembly 
lines of nonribosomal peptide synthetases (NRPSs) can be further subdivided into linear 
(a), iterative (b) and non-linear (c) [1].  The fungal type I  iterative PKSs (IPKSs) are 
classified as either highly-reducing (hr), partially reducing (pr), or non-reducing (nr) [2].  
This assembly line style of production lends itself to study by large molecule MS to 
characterize the proteins involved in the biosynthesis as well as the covalently-attached 
intermediate at each biosynthetic step, when recombinant proteins are available and 
activity reconstituted.   
  Regardless of type, enzymes involved in thiotemplate biosynthesis have 
enormous primary structures and can form some of the largest protein complexes within 
cells, sometimes larger than the ribosome [3]. The logic of thiotemplating offers two 
advantages – 1) substrate/intermediate shuttling through the pathway – intermediates 
cannot diffuse away, 2) potentially toxic intermediates are not allowed to affect the 
producing organism – a mechanism of host resistance.  In short, thiotemplate biosynthesis 
enables efficient and safe biosynthesis of highly active secondary metabolites.  Substrates 
are activated for entry into thiotemplate pathways by acyl-CoA ligases, acyl transferases 
(fatty acids and polyketides), or adenylation enzymes (nonribosomal peptides).  The 
energy of activation of each monomer is conserved throughout the pathway by 
transthioesterification along the assembly line until the final product is released.  
Biosynthetic mechanisms of NRPs and PKs share many common elements, most 
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important covalent tethering of intermediates to the assembly line.  This commonality 
allows for techniques specifically targeting this quality to be applied generally to 
thiotemplate systems.    
 
1.2 Mechanisms of Biosynthesis 
The basic enzymatic functions at the core of NRPSs – adenylation (A), thiolation 
(T) and condensation (C) are displayed in Fig. 1.1.  A domain set of A-T-C comprises 
one module of a NRPS and contains all the functions necessary for incorporation of one 
monomer [4].   Adenylation domains are the “gatekeepers” of the NRPS assembly line.  
These enzymes are composed of ~500 amino acids (50 kDa) and belong to the AMP-
binding super-family of enzymes.   Entry of monomers is regulated by specific domains 
for each monomer and requires ATP for activation.  A-domains contain a conserved D-K 
pair that is responsible for recognition of the amino and carboxyl ends of an amino acid 
and for coordination of the Mg2+ and ATP cofactors.  Substrate specificity of the A-
domain is derived from the residues lining the amino acid binding pocket. Well-
characterized systems can be used to predict the specificity of uncharacterized A-domains, 
which is a driving force behind proteomic based NRPS elucidations [1, 5, 6].  The 
adenylation domain catalyzes adenylation of the amino acid substrate carboxyl with AMP.  
The aminoacyl adenylate intermediate is short-lived and is a substrate for a 
transesterification to the free thiol of the T-domain active site.   
The smallest domains, referred to as thiolation or just carrier domains, are ~100 
amino acid (10 kDa) stretches that carry intermediates and owe their name to the free 
thiol of their phosphopantetheine (Ppant) cofactor.  The T-domain active site is well 
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conserved and contains the GG(H/D)SL phosphopantetheine attachment site motif.  The 
sole function of these domains is to covalently anchor a ~20 Å swinging arm that can 
move from active site to active site shuttling intermediates along the assembly line.  The 
Ppant cofactor is derived from CoA and is attached to the T-domain active site serine 
through a phosphopantetheinyl transferase most often acting in trans.  Condensation 
domains are composed of ~500 amino acids and catalyze amide bond formation between 
intermediates on adjacent T-domains.  These enzymes carry a signature HHXXXDG 
motif essential for catalysis.  The second H in the strictly conserved motif is proposed to 
activate the acceptor amino group so that it can act as a nucleophile and attack the donor 
thioester.  The donor T-domain is now available for recharging by its A-domain and the 
newly formed dipeptide is ready for progression down the assembly line.  Peptide bond 
formation proceeds in this fashion until the end of the last module is reached.  Product 
release can be achieved by hydrolysis of the last thioester with or without 
macrocyclization [7] as seen in Fig. 1.2. 
In addition to these three basic functions for peptide elongation in NRPSs, there 
are several other tailoring activities in NRPS assembly lines, as seen in Fig. 1.3.  These 
include C- and N-methyltransferases, N-formyltransferases, amino transferases, L-D 
epimerases, oxidases, reductases, cyclases, and halogenases among others [8].  NRPS 
pathways may also be integrated into hybrid NRPS-PKS pathways, as seen with 
emericellamide [9], and the final products may be decorated with lipid and/or 
carbohydrate moieties. Given these extensive biotransformations in NRPSs, the peptide 
products exhibit a diverse array of structures and biological effects. 
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PKS core activities of monomer selection (AT), tethering (T, acyl carrier protein 
(ACP)), and condensation (KS) functions are analogous to the A-, T-, and C- domains of 
NRPSs and highly related to the AT- ACP- and KS- domains involved in fatty acid 
synthesis [10].  AT domains are ~45 kDa enzymes that select acyl-CoA starter and 
extender units  for chain initiation and elongation [11].  The AT-domains attack the 
starter and extender CoA thioester bonds with a conserved serine nucleophile forming a 
transient covalent intermediate that is the substrate for KSs (for initiation) and ACPs (for 
elongation) [12].  The T-domains of PKSs are very similar to those of NRPSs and are 
approximately the same size, 8-10 kDa.  The KS is a ~50 kDa enzyme that catalyzes 
Claisen condensation between T-domain and KS-domain bound substrates using a 
conserved cysteine residue [13].  In addition to these minimal functions, PKSs may also 
include ketoreductase (KR), dehydratase (DH) and enoyl reductase (ER), cyclase (Cyc), 
thioesterase (TE), C-methyl transferase (C-MT) activities, among others [14].  The 
diversity in PK structure and activity relies on stereocenters introduced by KRs, degree of 
reduction, cyclization, aromatization and decoration of the ketide core as opposed to 
NRPs that owe most of their structural diversity to monomer selection. 
PKSs can be categorized into three different types, type I, type II and type III, although 
blurring between the categories has become evident from the growing wealth of DNA 
sequence [15].  Enzymatic functions are shared between the types; however quaternary 
structure and chain initiation and termination are different.  Type I PKSs are monolithic 
enzymes comprised of multiple active sites along one polypeptide chain.  Type II PKSs 
are a set of discrete enzymes that act iteratively to produce a polyketide.  Type II PKSs 
utilize stand- alone T-domains.  In addition they minimally consist of a KS and chain-
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length factor (CLF) that are typically encoded by distinct genes.  The CLF is an inactive 
KS enzyme that provides a cavity for the nascent ketide chain to extend into, the depth of 
which governs ultimate chain length [16].  Type III PKSs use acyl-CoAs but no T-
domain and have a single KS which initiates, tethers, extends and terminates the 
polyketide chain.  They function as homodimers and are roughly ~45 kDa in size.  Type 
III PKSs are typically thought of as plant enzymes; however, there are examples of 
bacterial and fungal type III PKSs [17, 18].  For fungi, the most commonly used mode is 
the type I PKS.  In fungi, unlike bacteria, the type I PKSs use a single KS-AT-T module 
repeatedly and are hence referred to as type I iterative PKSs (IPKSs).  These IPKSs can 
be further subdivided into non-reducing (nr), partially-reducing (pr) and highly-reducing 
(hr) IPKSs [19].  Theses qualifications reflect the presence or absence of PKS reducing 
functions, the KR, DH and ER domains. 
 PKs, unlike NRPs must undergo extensive on assembly-line transformations in 
order to achieve complex structural content.  The presence of the optional ketoreductase 
(KR), dehydratase (DH) and enoyl reductase (ER) functions after initial activation allows 
for reduced C-C bonds and chemical stability for linear or macrocyclic PKs (Fig. 1.4).  
Stereocenters introduced by the action of KRs that are not further reduced by DH and/or 
ER enzymes contribute to the diversity in structure PK products possess [20].   Absence 
of theses reducing functions results in highly reactive poly-carbonyl backbones that 
undergo aromatization and cyclization guided by product template (PT) domains [21, 22]. 
C-methyl transferases (C-MT) and utilization of alternate acyl-CoAs such as methyl-
malonyl- CoA, results in addition of branched structures to the backbone.  Additionally, 
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like NRPs, PKs can undergo post assembly line tailoring by O-methyl transferases, 
glycosylases and others [23].   
While there are no well-defined rules regarding differences between fungal and 
bacterial NRPSs and PKSs, there are some general trends that distinguish them (Fig. 1.5, 
1.6).  First, fungal pathways tend to be mostly large megasynthetases (type I) while 
bacterial pathways tend more toward modularity (type II).  Bacterial NRPSs generally 
terminate by the action of a thioesterase (TE) domain whereas fungal NRPSs tend to 
terminate by the action of a terminal condensation domain.  Another distinguishing 
characteristic of fungal NRPSs is that many fungal A-domains have an inserted N-
methyltransferase domain [24].  Fungal type I PKSs tend to follow the iterative model; 
each domain acts repeatedly activating and modifying the same monomers.  Serial use of 
the same set of enzymatic functions can result in polyketides dominated by one structural 
motif; these polyketides are characterized as non-reduced or highly reduced due to the 
presence or absence of PKS reducing functions in the synthase.  In addition, presence of 
KR or KR and DH domains (but not ER domains) results in an intermediate class of 
partially reduced polyketides.  Bacterial type I PKSs act modularly; each domain acts 
once.  Large polyketides require multiple large enzymes for biosynthesis in bacteria, 
because each domain functions once in the bacterial systems.  A benefit of modularity is 
it allows for mixing of non-reducing and reducing modules.  Both bacteria and fungi have 
numerous hybrid NRPS-PKS pathways.  Both fungal and bacterial pathways are often 
clustered together on the genome, but fungal pathways may be split onto separate 
chromosomes [25].  Generally, fungal thiotemplate genes do not contain introns or only 
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contain a few introns, however as more fungal genomes are sequenced it has become 
apparent this is not always the case [26]. 
 
1.3 Protein Level Analysis of Thiotemplate Enzymes 
  Bioinformatic analyses often provide successful prediction of adenylation 
domain specificity; however, in vitro analysis should always be performed to fully 
characterize a biosynthetic pathway (particularly for orphan gene clusters where the 
metabolite produced is unknown).  The traditional methods used to analyze substrate 
specificity of adenylation domains have relied on the pyrophosphate exchange assay, 
autoradiography or radio TLC [27-29].  While these methods are sensitive, they cannot 
be used to determine substrate specificity of adenylation domains in a complex or 
undefined mixture such as the native metabolome.  In addition, analysis may be 
hampered by unavailability of radiolabeled substrates.  Radiolabeling also has a deficit in 
that it does not report on any further transformations to the substrate once tethered to the 
carrier protein by the activating module or other enzymes present in a reaction mixture.    
An example of domain specificity investigation by Dorrestein, et al. [30] included 
the presentation of nine adenylation-carrier protein di-domain proteins with a pool of 
substrates of defined content in addition to a full metabolome, followed by identification 
of intermediates in seven pathways.  An example of the workflow is shown in Fig. 1.8A.  
Interpretation of specificity was accomplished using high resolution mass spectrometry 
for proteins or peptides with covalently tethered phosphopantetheine (Ppant) bound 
intermediates and discrimination between potential intermediates differing in mass by as 
little as two daltons.  Due to the labile nature of the Ppant arm, selective ejection of the 
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complex from the peptide or enzyme containing it in the mass spectrometer is used in a 
technique known as the “Ppant ejection assay” [31].  Using MS, gentle fragmentation of a 
mixture containing phosphopantetheinylated peptides leads to identification of T-domain 
active sites and the identity of the intermediate(s) bound to them.  Since the focus of 
analysis is now the small molecule cofactor and bound intermediate(s), accurate 
precursor mass assignment is no longer a prerequisite for accurately determining the 
identity of the bound intermediate (Fig. 1.8B).  Dorrestein, et al. pioneered this technique 
for in vitro characterization by partially elucidating seven systems and extending the 
analysis to a 126 kDa protein and its bound intermediate.  When performed on a Fourier-
Transform mass spectrometer (FTMS), the Ppant ejection assay discerns between 
intermediates differing by one dalton as exemplified by the discrimination between 
acetoacetate and β-aminobutyrate loaded carrier proteins from the mycosubtilin pathway 
of B. subtilis [32].   
In addition to determining substrate specificity of activating domains, the Ppant 
ejection assay can be used to monitor transformations occurring to the covalently bound 
substrate.  Dorrestein, et al. were able to monitor the dehydration and subsequent 
rehydration of a polyketide intermediate in vitro. Notable was the use of a bench-top 
mass spectrometer, demonstrating how this type of analysis can be performed in 
laboratories with access to standard mass spectrometers.  The ability of the Ppant ejection 
assay to shift analysis towards low mass is significant because at masses above 70 kDa or 
so, intact mass alone cannot discriminate between intermediates that are close (<2 Da) in 
mass due to complex isotopic distributions and low signals at high MW.  Lee, et al. 
extended analysis in this high mass regime to determine the substrate specificity of a 108 
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kDa synthetase in a multiplexed assay [33].  Since 2006, about a dozen labs have 
employed the Ppant ejection assay using a variety of mass spectrometers to characterize 
thiotemplate systems in vitro [34-39].   
Mass spectrometric tools for the in vitro characterization of recombinantly 
produced enzymes are now well developed.  The advent of a technique called PrISM (for 
Proteomic Investigation of Secondary Metabolism, see Fig. 1.9A) now enables the 
investigation of thiotemplate systems closer to the in vivo level [40].  Bumpus, et al. have 
shown that identification of T-domain active site peptides can be carried out on crude 
lysates of recombinantly produced enzymes in addition to full proteomic mixtures of 
bacterial enzymes at the native expression level. Indeed, the Ppant ejection assay can be 
used to accurately identify phosphopantetheinylated peptides in full proteome-scale 
digests.  The Ppant ejection assay is very robust because the mass of the Ppant ion is 
measured so accurately (i.e., <2 part-per-million error) that the detection of thiotemplate 
biosynthetic pathways can be highly selective.  These features allow for the Ppant 
ejection assay to be used in the PrISM workflow for monitoring expression of targeted 
systems and for the discovery of thiotemplate systems (even with no genome sequence).  
PrISM has been demonstrated in the proteome of an unsequenced Bacillus for the 
identification of a NRPS and hybrid NRPS-PKS gene clusters and association of the 
small molecule products to their biosynthetic enzymes.  
Labeling of carrier proteins by in vivo phosphopantetheinylation or metabolic 
incorporation of CoA analogues is an approach complementary to PrISM.  La Clair et al. 
synthesized a variety of CoA analogues for chemoenzymatic labeling of carrier proteins 
using the promiscuous phosphopantetheinyl transferase Sfp from B. subtilis [41].  
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Chemical conjugation of fluorescent probes to CoA enabled quantitative and qualitative 
assessment of in vivo phosphopantetheinylation as well as detection of carrier protein 
containing recombinant enzymes at levels below that detectable by standard SDS-PAGE 
analysis.  Biotinylated CoA analogues were also synthesized and used to pull down non-
denatured carrier protein containing enzymes.  Meier et al. extended this work by 
synthesizing a collection of bioorthogonal pantetheine analogues for in vivo labeling of 
carrier proteins [42].  Advantages of moving towards using smaller pantetheine analogues 
as opposed to CoA analogues are ease of synthesis, stability of the compounds and 
increased efficiency of metabolic incorporation due to easier transport across membranes.  
The pantetheine analogues synthesized were shown to be incorporated into CoA 
analogues both in the in vitro reconstituted CoA biosynthetic pathway as well as into the 
endogenous CoA biosynthetic pathway of E. coli.  The authors used the in vitro and in 
vivo synthesized CoA analogues to successfully modify VibB from the vibriobactin 
pathway of V. cholerae recombinantly expressed in E. coli with purified or co-expressed 
Sfp.  In a follow-up study, Meier et al. synthesized fluorescent acyl transferase, 
ketosynthase and thioesterase activity based probes and combined them with previously 
synthesized carrier protein probes [43].  The combined set of probes was shown to be 
active in vivo for labeling a purified PKS (PikAIII, pikromycin from S. venezuale) and a 
NRPS TE domain (Tyc-TE, tyrocidine from B. brevis).  The probe set was used in vivo to 
profile fatty acid biosynthesis proteins from cultured human cells and SrfAC, an NRPS 
involved in surfactin biosynthesis in B. subtilis.  These kinds of reagents have helped 
established a new method termed OASIS (for Orthogonal Active Site Identification 
System, Fig. 9B), which is a new method that couples the metabolic labeling of 
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thiotemplate enzymes with mass spectrometry based proteomics [44].  OASIS was 
successful in enriching, identifying and profiling proteins of all four NRPS and PKS 
pathways from B. subtilis, and holds promise for discovery of thiotemplate systems in 
unsequenced genomes. In conclusion, a number of proteomic techniques have been 
developed and used to identify mechanisms of bacterial NRPS biosynthesis. 
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 1.4 Figures  
 
 
 
Fig. 1.1.  Basic enzymatic domains and their reactions for non-ribosomal peptide 
synthesis; A: adenylation, T: thiolation, and C: condensation.   
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 Fig. 1.2.  Basic enzymatic domains and their reactions for polyketide synthesis; AT: 
acyltransferase, T: thiolation, and KS: ketosynthase.   
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 Fig. 1.3.  Some typical NRPS tailoring domains and their catalyzed reactions; AMT: N-
methyl transferase (preferentially found in fungi), E: epimerase, and TE: thioesterase. 
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 Fig. 1.4.  Some typical PKS tailoring domains and their catalyzed reactions; KR: 
ketoreductase, DH: dehydratase, and ER: enoyl reductase. R = ribose-ADP(P).  The KR 
and ER domains are NADPH dependent enzymes.
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 Fig. 1.5.  Overview of fungal vs. bacterial NRPSs.  NRPSs can be divided into three types, linear (a), iterative (b) and non-linear (c).  
Fungal NRPSs generally follow a single megasynthetase logic, whereas bacterial NRPS pathways are generally spread over a greater 
number of polypeptides.  Fungal NRPSs are also rich in A-MT domains, a feature rarely seen in bacterial NRPSs.  CsS: cyclosporine 
synthetase; EnS:  enniatin synthetase; Pes1: synthetase encoded by pes1, TycA, B, C:  tyrocidine synthetase A, B, C; GrsA, B:  
gramicidin S synthetase A, B; SyrB1, E:  syringomycin synthetase B1, F.
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 Fig. 1.6.  Overview of fungal vs. bacterial type I PKSs. Type I PKSs can be divided into three types, non-reducing (nr), partially-
reducing (pr) and highly-reducing (hr).  Fungal type I PKSs generally follow an iterative logic using a single AT, KS, and T iteratively, 
whereas bacterial type I PKS use modules of PKS machinery sequentially. PksA, polyketide synthase A from aflatoxin biosynthesis; 
6-MSAS, 6-methyl salicylic acid cynthase; TENS, tenellin synthase; DEBS, 6-deoxyerythronolide B synthase.
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Fig. 1.7.  Some fungal- and bacterial-derived compounds, 1 –10. 
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 Fig. 1.8.  Overview of mass spectrometric techniques for analyzing activity in vitro.  A) 
The activity based screening method is an in vitro assay for determining substrate 
specificity of NRPSs using a complex substrate pool and an accurate mass shift (Δm) as 
the readout.  FTMS enables resolution and accurate assignment of covalently-bound 
intermediates.  B) The Ppant ejection assay simplifies complex mass spectra of peptides 
or intact proteins by selectively ejecting phosphopantetheine and phosphopantetheine 
bound intermediates allowing for correct intermediate assignment even at high intact 
mass. 
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Fig. 1.9.  Overview of proteomic techniques for detecting the expression of thiotemplate enzymes in vivo.  A)  The PrISM workflow 
incorporates the “Ppant ejection assay” for the selective identification of thiotemplate enzymes.  The workflow utilizes tandem mass 
spectrometric data of thiotemplate enzymes as a starting point for the cloning and analysis of thiotemplate pathways.  B)  OASIS 
utilizes thiotemplate-specific metabolic labeling with affinity tags to allow for enrichment and identification of thiotemplate pathways.
 21
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CHAPTER 2 
 
REENGINEERING OF THE NONRIBOSOMAL PEPTIDE ANDRIMID  
 
2.1 Background 
Many lead compounds in development for new drugs derive from natural peptides and 
polyketides whose similar biosynthetic enzymes have been difficult to engineer for production of 
new derivatives.  Problems with generating multiple analogs in a single experiment along with lack 
of high-throughput methods for structure-based screening have slowed progress in this area.  
Another limiting factor in repurposing these mega-enzymes of secondary metabolism has been that 
commonly used hosts such as E. coli often give lower product titers.  Despite robust prediction of 
substrates via the “NRPS Code” [1-3], engineering of adenylation domains has been elusive.  
Combinatorial biosynthesis [4-8], the goal of expanding the natural products made by a biosynthetic 
pathway in order to generate different and potentially more useful compound has been an active 
area of research for many years going back to initial mutasynthesis experiments more than 50 years 
ago[9].  The main approach used in reengineering NRPSs has employed construction of chimeric 
synthetases where an A-domain of one NRPS is replaced by an A-domain from another NRPS that 
activates a different substrate.  This so-called “domain swapping” strategy can prove successful in 
terms of generating the desired product, but has been plagued by decrease in product yield 
presumably due to interruption of protein-protein interactions brought on by this cut and paste 
approach [10-17].  In addition, domain swapping is not ideal for true combinatorial biosynthesis in 
that at most one variant of an NRP can be generated per swap.  This chapter describes an example 
of using directed evolution applied to engineering of thiotemplated biosynthetic systems, with mass 
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spectrometry serving as a structure-based screen for the mutant library created in the native 
producer and isolation of three mutants that produce robust levels of three new andrimid derivatives. 
The particular incarnation of directed evolution utilized here is oligonucleotide-directed 
saturation mutagenesis.  The benefits of this strategy as opposed to domain swapping or making 
point mutants are that the enzyme of interest is altered only at or near the substrate binding site 
and that thousands of enzyme variants are generated in parallel.  Presented in this chapter, 
directed evolution and a multiplexed screen of a mutant library with 14,330 members were used 
to generate three new derivatives of the antibacterial compound, andrimid (1) (Fig. 2.1). 
Andrimid, a hybrid NRP/PK molecule produced by Pantoea agglomerans [18-20] is a broad 
spectrum antibiotic.   Andrimid acts by inhibiting fatty acid biosynthesis at the acetyl CoA 
carboxylase step, preventing biosynthesis of malonyl CoA, the precursor for fatty acids as well 
as many polyketides [21].  Previous structure-activity relationship (SAR) studies identified a 
portion of andrimid, the valine subunit, that could be exchanged to create more potent and 
specific compounds [22].  Domain swapping experiments on the corresponding NRPS gene, 
admK, showed that the valine subunit could be substituted for isoleucine and that there was no 
apparent editing by downstream condensing enzymes [23] allowing generation of an andrimid 
derivatives in vivo [24]. 
 
2.2 Experimental Procedures 
Chemicals and Reagents:  Restriction enzymes were from Invitrogen (Carlsbad, CA), T4 
DNA ligase was from New England Biolabs (Ipswich, MA), Phusion polymerase from 
Finnzymes (Worburn, MA) was used for PCR.  Growth medium was from BD Biosciences (San 
Jose, CA).  Oligonucleotides were purchased from Integrated DNA Technologies (Coralville, 
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IA) and are listed in Table 2.1.  HPLC solvents were from Fisher (Pittsburgh, PA).  Formic Acid 
was from Acros Organics (Geel, Belgium).  PCR cleanup, plasmid miniprep and gel extraction 
kits were from Qiagen (Valencia, CA).  Stable-isotope labeled amino acids were from 
Cambridge Isotopes (Andover, MA).   All other reagents, chemical and consumables were from 
Sigma unless otherwise specified. 
 
Strains and Plasmids:  E. coli DH5α λ pir was used for all cloning steps for plasmids 
containing oriR6K.  E. coli DH5α and BL21(DE3) were obtained from the UIUC Cell Media 
Facility.  E. coli imp ASR, Klebsiella pneumoniae ATCC 13883, Staphylococcus aureus ATCC 
25923, and Enterococcus faecalis ATCC 19433 were used as the indicator strains for agar 
overlay assays.  The andrimid producer, P. agglomerans Eh 335 and E. coli imp ASR were a gift 
from Christopher T. Walsh.  K. pneumoniae ATCC 13883, S. aureus ATCC 25923, and E. 
faecalis ATCC 19433 were obtained from ATCC (Manassas, VA).  All strains were cultured in 
LB or 2xYT at 37° C (E. coli, K. pneumoniae, S. aureus and E. faecalis) or 28° C (P. 
agglomerans).  Plasmid pQE60 (Qiagen) was used for expression of admK in P. agglomerans.  
Plasmids pACYC-Duet, pET-Duet, pET28a and pUC-19 were obtained from Novagen 
(Darmstadt, Germany).  The suicide plasmid pMQ118 was obtained from Presque Isle Cultures 
(Erie, PA).  All strains and plasmids are listed with relevant characteristics in Table 2.2. 
 
Antibiotic Bioassays:  100 mm diameter LB agar plates were overlaid with 4 mL molten 
LB agar inoculated with 75 µL of an overnight culture of the indicator strain.  The inoculated top 
agar was allowed to solidify before sterile paper disks were laid onto the assay plates.  Onto each 
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disk 10-20 µL of sterile filtered culture supernatant or control was spotted before incubation at 
37 ºC overnight or until zones of inhibition were visible. 
 
DNA Sequencing:  DNA sequencing was carried out at the University of Illinois core 
sequencing facility on an ABI 3730XL capillary sequencer on reactions using BigDye Version 
3.0 terminator/enzyme mix and standard protocols.  Sequence outputs were assembled and 
analyzed using Sequencher 4.6 software (Gene Codes, Ann Arbor, MI). 
 
Mass Spectrometry:  A 7 Tesla LTQ-FT equipped with a Surveyor autosampler and a MS 
pump was used for all mass spectrometric analysis (Thermo-Fisher Scientific).  Andrimid and its 
derivatives were analyzed using a Jupiter 4.6 X 150 mm C18 HPLC column (Phenomenex) and a 
gradient of 0-75% ACN over 35 minutes.  LC solvents (water and acetonitrile) contained 0.1% 
formic acid.  Initial screening was performed at low (ion-trap) resolution with a selected ion 
monitoring (SIM) window from m/z 435-535 as the full scan and data-dependent fragmentation 
of the top 10 peaks from the full scan.  Confirmation of derivative production was carried out 
using the same scans but in high (FT, 100,000) resolution.  Mass spectrometric data was 
analyzed using Qual Browser software (Thermo-Fisher Scientific). 
 
Construction of Plasmid pPAAR:  A suicide plasmid was constructed in order to facilitate 
deletion of admK from the P. agglomerans chromosome.  The P. agglomerans rpsL gene was 
amplified from genomic DNA using primers rpsL-F and rpsL-R modified from primers AJ 44 
and AJ45 [25], digested with NotI and XhoI and ligated into similarly digested pMQ118 [26] to 
yield a plasmid containing oriR6K, oriT, kanR, P. agglomerans rpsL and the pMQ118 multiple 
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cloning site.  The kanamycin resistance marker of the aforementioned plasmid was replaced with 
a chloramphenicol resistance marker to avoid cross resistance between aminoglycosides.  Cat 
was amplified from pACYC-Duet (Novagen) using primers CatF and CatR, digested with BglII 
and NotI, gel purified and ligated into similarly digested and purified backbone to yield plasmid 
pPAAR (Pantoea agglomerans allele replacement).   
 
Deletion of admK from the P. agglomerans Chromosome:  A ΔadmK mutant of P. 
agglomerans was generated to remove wild type activity prior to introduction of admK variants.  
A scarless deletion was obtained by transformation of a suicide plasmid containing a cat 
selection marker and rpsL counterselection marker along with a deletion cassette to serve as a 
region of homology.  The deletion cassette consists of 1000 bp of upstream and downstream 
sequence of the target region (admK) to serve as homology arms.  Replacing admK is a short 
spacer consisting of the first 15 and last 15 nucleotides of admK.  The left hand portion of the 
deletion cassette was generated by PCR amplification from genomic DNA using primers AdmK-
DelFL and AdmK-DelRL, the right hand portion of the deletion cassette was generated by PCR 
amplification using primers AdmK-DelFR and AdmK-DelRR.  The two portions of the deletion 
cassette were gel purified prior to assembly by overlap extension and subsequently amplified 
using primers AdmK-DelFL and AdmK-DelRR.  The deletion cassette was ligated into SmaI 
digested pUC-19 and transformed into E. coli for amplification prior to sequencing.  A plasmid 
miniprep of a clone with the correct sequence was digested with BamHI and EcoRI, gel purified 
and ligated into similarly digested and purified pPAAR to yield pPAAR-ΔadmK.    
A streptomycin resistant mutant of P. agglomerans was isolated to serve as a background 
strain for counterselection by plating several saturated 5 mL cultures onto LB agar containing 
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200 μg/mL streptomycin.  Several spontaneous mutants were obtained.  One StrR isolate was 
made electrocompetent using standard techniques, transformed with pPAAR-ΔadmK and plated 
on LB/Cam (25 µg/mL) to select for a crossover event resulting chromosomal integration of the 
plasmid.  Several integrants were picked, streaked out, and grown non-selectively before 
streaking onto LB/Str (200 µg/mL) to select for a second crossover event that results in 
resolution and loss of the plasmid.  Several colonies were picked and assayed by PCR and 
bioassay for loss of admK. 
 
Rescue of Bioactivity in the ΔadmK Mutant:  AdmK was amplified from genomic DNA 
using primers AdmK-F and AdmK-R, digested with NcoI and HindIII and ligated into similarly 
digested pQE60.  The resulting plasmid was transformed into electrocompetent P. agglomerans 
ΔadmK and assayed for restored bioactivity using an agar overlay assay. 
Alignment of admK to other adenylation domains and extraction of binding pocket residues:  
Several adenylation domains with specificity for the desired activity in the admK (gb accession 
number AAO39105.1) were aligned:  GrsA (gb accession number CAA33603.1, phenylalanine 
specific), TycB M3 (gb accession number AAC45929.1, phenylalanine specific), McyA M2 (gb 
accession number CAO90227.1, alanine specific), JamO_( gb accession number AAS98786.1, 
alanine specific), BacA M1 (gb accession number AAC06346.1, isoleucine specific), FenB (gb 
accession number AAB00093.1, isoleucine specific), SrfAB M3 (gb accession number 
BAA08983.1, leucine specific), GrsB M4 (gb accession number CAA43838.1, leucine specific) 
and LicB M1 (gb accession number AAD04758.1, valine specific).  Adenylation domains were 
aligned using the program CLUSTALX [27].  Positions aligning to D235, A236, W239, T278, 
I299, A301, A322, I330, C331 and K517 of GrsA were extracted as the putative binding pocket 
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residues [3].  The binding pocket residues were inspected for their variation across the aligned 
sequences and three positions corresponding to T278, I299 and A322 in GrsA were chosen for 
mutagenesis. 
 
Generation of admK Mutant Libraries:  A three site limited saturation mutagenesis 
library was generated by combined megaprimer and overlap extension PCR.  The 5’portion of 
the library was generated by amplification from genomic DNA with primers AdmK-F and 3-
Site1-R.  The PCR product was gel purified and used as the forward megaprimer in a subsequent 
PCR reaction with primer 3-Site2-R and genomic DNA as template.  The 3’portion of the library 
was generated by amplification from genomic DNA with primers 3-Site3-F and AdmK-R.  The 
PCR product was gel purified and used a megaprimer in a subsequent PCR reaction with primer 
3-Site2-F and genomic DNA as template.  The two halves of the AdmK 3-Site library were gel 
purified and assembled by overlap extension before amplification with primers AdmK-F and 
AdmK-R.  The final PCR product was digested with NcoI and HindIII before gel purification 
and ligation into pQE60 that had been digested and purified similarly. 
 
Screening of the admK Mutant Libraries:  The admK mutant libraries were transformed 
into electrocompetent P. agglomerans ΔadmK and plated onto LB-Amp100 in vented Q-trays 
(Genetix) and grown overnight before using a VersArray (BioRad) colony picker to array the 
clones into deep well 384-well (AB Gene) master plates containing LB-Amp (100 µg/mL) with 
5% glycerol.  Clones were assayed by replicating into assay plates. Assays were carried out in 
deep well 96-well plates (Whatman) containing 1.2 mL 2xYT Amp 100 µg/mL.  Assay cultures 
were grown 24 hours then assayed for production of variant andrimid.  Eighteen μL from each 
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well of a 96-well plate was taken and pooled into one well of a similar 96-well plate using a 
Matrix Technologies (Thermo-Fisher) pipetting robot.  Each well was filtered through a 0.22 μm 
particle filter after centrifugation to remove suspended cells.  Each pooled sample represents one 
assay by LC-MS/MS.  Hits were determined from those LC-MS/MS injections that gave marker 
ions for the andrimid backbone at m/z 268.13 and 226.12 (Supplementary Figure 4a).  Wells that 
gave hits from the pooled samples were isolated by performing row and column pooling of the 
plate from which the 96-well pool came from.  Andrimid derivative production was verified by 
LC-MS/MS using FTMS for detection of both intact and fragment ions (i.e. <2 part-per-million 
mass accuracy).  Clones producing andrimid derivatives were subjected to targeted DNA 
sequencing of the mutant admK gene. 
 
Estimation of Mass Spectrometric vs. Bioassay Sensitivity:  The estimation of relative 
sensitivity for MS vs. a classic halo assay on plates is based on the limit of detection (LOD) 
during MS of andrimid, which is 20 fmol.  Given that 96 samples are mixed per LC-MS injection, 
this translates to an effective LOD of 1.9 nmol.  The MIC data for andrimid against E. coli shows 
that 0.47 nmol of andrimid can be detected in a 10 uL spot in the agar overlay assay.  If this 
bioassay were diluted by 96 fold using a similar pooling strategy as the LC-MS assay, that means 
I could only detect andrimid if there was 45.12 nmol present in one 96th of the pool.  This 
calculation gives the approximate value of 23.5 fold for an estimated sensitivity difference 
between MS and the bioassay as implemented in this study 
 
Isolation and Quantitation of Andrimid and Analogues:  Andrimid was produced from 
liquid culture of P. agglomerans in 2xYT supplemented with antibiotics and amino acids as 
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required for 28 ºC for 24 hours.  Cells were removed by centrifugation followed by filtration 
through a 0.45 µm membrane (Millipore, Billerica, MA).  Filtered culture supernatant was 
extracted three times with one-half volume ethyl acetate.  Ethyl acetate fractions were combined 
and dried under vacuum.  The crude extract was dissolved in 50:50 water: methanol and 
extracted with 9 volumes of hexane.  The water:methanol fraction was then extracted with one 
half volume methylene chloride.  The methylene chloride fraction was dried under vacuum and 
then dissolved in 10 mL 20% acetonitrile and applied to a 12 cc C18 SPE column (Whatman, 
Piscataway, NJ) equilibrated with 20% acetonitrile.  The column was washed with 2 volumes 
40% acetonitrile and eluted with one volume 80% acetonitrile.  The eluate was dried and 
dissolved in 20% acetonitrile then loaded onto a 10 x 150 mm Eclipse C18 column (Agilent, 
Santa Clara, CA).  Andrimid and analogues were eluted from the column using a linear gradient 
0-70% acetonitrile over 30 minutes.  Andrimid and analogues eluted as pure peaks from 25-32 
minutes.  Peak purity and yield were determined by a LC-MS assay using the same column, 
gradient and mass spectrometer used in screening the mutant library calibrated with standards at 
known concentrations. 
 
Stable Isotope Feeding Study:  Mutants A2 and B12 were grown in M9 medium 
supplemented with 0.1% yeast extract, 0.1% caseaminoacids and 50 mM each of 13C2 leucine 
and/or 13C6 isoleucine (Cambridge Isotopes) for 24 hours at 30 ºC.  The culture supernatants 
were syringe filtered and analyzed using the LC-MS/MS method outlined above. 
 
MIC Determination:  150 mm diameter LB agar plates were overlaid with 12 mL molten 
LB agar inoculated with 225 µL of OD600 = 0.8 indicator strain.  The inoculated top agar was 
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allowed to solidify before sterile paper disks were laid onto the assay plates.  10 µL of antibiotic 
was spotted onto the disks and plates were incubated 8 hours at 37 ºC.  Zones of inhibition were 
defined as the radius and measured using calipers.  Zones of inhibition were plotted against 
Log10 of the concentration of spotted antibiotic.  MICs were defined as the minimum 
concentration required yielding a 1 mm zone of inhibition and calculated by nonlinear regression 
using the software package GraphPad Prism (La Jolla, CA). 
 
2.3 Results and Discussion 
In order to accomplish expression of a library of mutant enzymes and monitor the 
effectiveness of the mutations by screening for end products produced by the pathway in vivo, 
removal of the wild type (WT) enzyme activity was necessary.  An allele replacement strategy 
based on homologous recombination that has proven successful in a number of organisms, 
namely the streptomycin resistance counterselection [28] was chosen.  Briefly, this approach 
relies on the fact that the WT rpsL allele is dominant over the streptomycin resistant allele.  
Therefore, in a streptomycin resistant background, streptomycin resistance can be used to select 
for loss of chromosomal DNA containing the rpsL allele.  The first requirement was the isolation 
of a streptomycin resistant clone of the target strain, in this case P. agglomerans.  Next the wild 
type rpsL allele was cloned into a plasmid to serve as a counterselectable marker (Fig. 2.2).  The 
plasmid contains a selectable marker, as well as a copy of the allele to replace the target gene to 
serve as a region of homology. In addition, the vector used was a suicide plasmid, unable to 
replicate in P. agglomerans.  The completed plasmid construct was transformed into P. 
agglomerans; growth on medium containing chloramphenicol was only supported once the 
plasmid recombined with the chromosome.  The WT rpsL allele is dominant over the 
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streptomycin resistant allele, therefore selection on streptomycin containing media selected for a 
second recombination event in which one half of the recombinants were the WT and one half 
contained the allele originally on the plasmid construct.  Using this strategy a ΔadmK mutant was 
isolated to serve as a background strain for expression of an admK mutant library; this result was 
validated by PCR (Fig 2.3).  The E. coli expression plasmid pQE60 was found to be capable of 
supplying admK and restoring andrimid production levels comparable to WT in P. agglomerans 
(Fig. 2.4). 
In order to select residues in admK for mutagenesis, sequence alignments of admK with 
A-domains known to activate substrates different than the valine were constructed and analyzed 
(Fig 2.5).  A-domains that activate aliphatic amino acids were chosen because SAR studies 
showed that this type of residue could substitute for valine and increase the potency and 
selectivity of the andrimid scaffold.  From the sequence alignment with the eight residues used 
for substrate prediction of NRPS A-domains [3], three of the eight that were highly variant were 
chosen for saturation mutagenesis (Fig. 2.6). The three-site saturation mutagenesis library 
resulted in 1,404 distinct mutants, and was limited by selection of codons for synthetase “code” 
residues likely to select aliphatic substrates for incorporation into the andrimid backbone.  The 
mutant library was constructed by utilizing sequential megaprimer and overlap extension PCRs 
[29, 30].  To insure 95% coverage of 1404 mutants, ~14,330 clones were screened.  Library 
statistics were calculated using the program GLUE [31].  GLUE analysis shows that the library is 
99.99% complete and that there is a 94.9% probability that the library contains all possible 
variants. 
Screening of the library of andrimid producing clones used a structure based assay.  
Using an antibiotic bioassay would not allow for discrimination between andrimid and 
 36
derivatives of andrimid, nor would it allow for identification of which precise andrimid 
derivative had been produced since it was likely that if any of the andrimid derivatives were 
produced, they would all be active antibiotics.  During initial assay evaluation, mass 
spectrometric-based detection of andrimid showed >20 fold greater sensitivity than a bioassay, 
and a fragmentation pattern that cleanly dissected the molecule into regions to be conserved or 
variant (Fig 2.7a).  These attributes of the MS-based screen allowed identification of which 
andrimid derivative was produced and for the screening of 96 clones in a single LC-MS run.  
Over 14,330 clones from 150 96-well plates of the three-site library were screened and four 
clones producing andrimid derivatives were isolated. Twenty-four percent of assay plates (i.e., 
96 samples combined into one) still showed production of andrimid while 41% of plates showed 
no production beyond the octatrienyl-β-phenylalanine precursor to andrimid (2).  Curiously, 
almost all of the plates assayed showed production of a species at m/z 433.21 that was 
determined to be octatrienyl-β-phenylalanyl-β-phenylalanine (3), a result apparently from 
“stuttering” by the transglutaminase AdmF, the enzyme responsible for incorporating β-
phenylalanine twice into the growing ketide-peptide chain. 
The four mutant clones were isolated and identified by row and column searching of the 
assay plates.  The isolated clones were then sequenced and designated A2 (W240L, G291V), A7 
(W240S, I265T, G291E), A9 (W240T, I265T, G291E) and B12 (R235K, W240L, I265L, 
G291E).  Together, these clones produced three new andrimid derivatives and another that has 
been described previously (Fig. 2.1).  Clones A2 and B12 were found to produce an andrimid 
related peak at m/z 494.26, corresponding to either isoleucine or leucine substituted andrimid (4, 
5) (Fig 2.1).  Clones A7 and A9 both produced a mixture of alanine and phenylalanine 
substituted andrimid (6, 7) (Fig. 2.7). In order to resolve the Ile/Leu ambiguity for clones A2 and 
 37
B12, an isotope feeding study was conducted.  Culturing of clones A2 and B12 in media 
supplemented with a 50:50 mixture of 13C2-Leu and 13C6-Ile demonstrated that both clones A2 
and B12 have preference for Ile over Leu, but at different levels of discrimination (Fig 2.8).  
Clone A2 showed a 4:1 preference for Ile to Leu, whereas clone B12 showed a 20:1 preference 
for Ile to Leu.  Control experiments where only one isotope labeled amino acid was 
supplemented clearly showed that when one amino acid is supplied in 50 mM excess, 
incorporation of that amino acid is efficient (Fig 2.9).  For that reason, a mutasynthesis strategy 
was employed where the desired amino acid to be incorporated was supplied in excess for scale 
up of fermentations in order to determine yield and bioactivity.  Applying this mutasynthesis 
strategy also improved the yield for clones A7 and A9.  Compounds 1, 4, 5 and 7 were all found 
to be bioactive in disk diffusion assays (Fig. 2.10).  When using mutasynthesis, yields were 
significantly improved, in some cases approaching WT levels (Table 2.3).  MICs were 
determined for several representative bacterial strains (Table 2.4). 
The work presented in this chapter takes on some of the challenges associated with 
enzyme engineering.  Rather than using a more conventional host for reengineering AdmK, the 
native host, P. agglomerans was used.  The benefit of this approach is that the experiment began 
with a higher specific activity for the andrimid pathway.  This point is important because, as 
expected when mutations were made to the active site of AdmK, although the goal of changing 
the enzyme’s substrate specificity was achieved, a hefty solubility penalty was paid.  Had the 
less efficient host E. coli been chosen, some clones with successfully altered substrate specificity 
may not have been detected.   Creating a mutant library of AdmK rather than performing several 
domain swapping experiments allowed generation of four andrimid derivatives in the same 
experiment while examining many solutions for each derivative simultaneously.  A key aspect of 
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this work that allowed for this combinatorial biosynthesis experiment is the readout of the mutant 
library.  The structure based assay is a direct readout of not just the AdmK variants’ activity, but 
also the output of the downstream enzymes.  Unlike many indirect assays of enzyme activity, for 
example enzyme coupled assays, etc., direct readout of the mutant activity in the integrated 
pathway better reflects the outcome of the mutagenesis.  The sensitivity of the mass 
spectrometric assay was such that it allowed use of a pooling strategy that increased the overall 
throughput of the assay.  Four mutants that exhibited altered substrate specificity, A2, A7, A9 
and B12 were found.  All showed a broadening of substrate specificity relative to the WT, with 
increased preference to substrates other than the cognate substrate, valine.  A surprising outcome 
is that the overall best performing mutant was actually a serendipitous quadruple mutant.  The 
fourth mutation in B12, R235K is likely an artifact of PCR.  This relatively higher activity and 
solubility of the B12 mutant over the others suggests that mutations outside the selectivity 
conferring code should be considered for future A-domain mutant libraries.   
Prediction of adenylation domain substrates is fairly robust [2].  Despite this, prediction 
of what active site mutations to make for a particular outcome is far less developed.  This study 
allowed the largest scale survey to date of what amino acid substitutions could be tolerated in the 
adenylation domain active site.  While many of the triple mutants that still yielded andrimid were 
not sequenced here, one can imagine a study of this scale and perhaps even a 4-site saturation 
mutagenesis study specifically aimed at determining empirically what sites are stable to mutation.  
This would effectively map out the functional outcome and sharply increase the predictive ability 
of active site mutants to new derivatives.   As suggested by the unexpected mutation in mutant 
B12, the specificity determinants for A-domains may need to be reevaluated.  
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  NRPs are one class of natural products that have been the subject of study not only for 
their medical uses, but also because their assembly-line-like biosynthetic mechanism, which 
lends itself to general strategies for reengineering.    These enzyme reengineering strategies have 
been referred to as combinatorial biosynthesis [7], a term used to draw a parallel to the organic 
synthesis strategy of combinatorial chemistry.  A key difference between many combinatorial 
biosynthesis studies and traditional combinatorial chemistry experiments is that, for many of the 
combinatorial biosynthesis studies, only one analog compound is generated per experiment in 
contrast to parallel synthesis of many related compounds typically used in chemical synthesis.  
Challenges to attaining the goal of true combinatorial biosynthesis include not only the general 
challenges of enzyme engineering, but also the methods used to evaluate the modified enzymes 
and pathways.  Conventional bioassay methods do not discriminate between compounds with 
similar activity and may be confounded by the fact that all analogs may not be produced at the 
same levels.   The field of NRPS reengineering still has challenges to overcome.  The results of 
this study have shown that while it is possible to generate libraries of A-domains capable of 
activating a variety of substrates the resultant analog compounds are still mostly produced at a 
vastly reduced level.  Without the benefit of new high resolution X-ray or NMR structures of 
NRPS domains to guide the design of NRPS pathways, the field of NRPS engineering will need 
to continue to make use of directed evolution approaches.  Alternative approaches to making 
mutant libraries such as family shuffling [32] should be employed in the future in order to 
address challenges of enzyme reengineering.  Techniques such as this would create larger mutant 
active site fragments and possibly lead to a more stable and active mutant enzyme.   
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2.4 Figures and Tables: 
 
Figure 2.1.  Structures of andrimid and variants produced in this study.  1 andrimid, 2 
octatrienyl-β-phenylalanine, 3 octatrienyl-β-phenylalanyl- β-phenylalanine, 4 isoleucine-
andrimid, 5 leucine-andrimid, 6 alanine-andrimid, 7 phenylalanine-andrimid. 
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 Figure 2.2.   Homologous Recombination Used to Generate ΔadmK Strain of P. agglomerans. 
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 Figure 2.3.   PCR Assays Showing Deletion of the admK gene from P. agglomerans 
Chromosome 
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Figure 2.4. Agar Overlay Bioassay of WT and Mutant Strains of Adrimid-producing P. 
agglomerans.  Background Strain Construction.  StrR mutant maintains bioactivity comparable to 
WT. I mutant shows polar effects of operon disruption, Δ mutant is defective for bioactivity, 
transformation of Δ with vector does not restore bioactivity whereas transformation of Δ with 
vector + admK does.  WT, P. agglomerans Eh 335; StrR, PAG rpsL; I, PAG rpsL 
admJ/L::pPAAR ΔadmK; Δ, PAG ΔK; vector, PAG ΔK pQE60; vector + admK, PAG ΔK 
pQE60 admK.
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 Figure 2.5.  Alignment of admK to adenylation domains specific for desired alternate substrate.  Consensus aliphatic residues colored 
yellow, consensus aromatic residues colored orange, consensus polar residues colored green, consensus negative residues colored red, 
and consensus positive residues colored blue.  Constructed with CLUSTAL X [27], using default settings.
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Figure 2.6.  Nonribosomal code residues extracted from grsA, admk and aliphatic amino acid 
consensus sequences.  Strictly conserved residues are highlighted in blue, highly conserved 
residues are highlighted in green and highly variant residues targeted for limited saturation 
mutagenesis are highlighted in red. 
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Figure 2.7.  High resolution mass spectra of andrimid analogs produced.  Fragmentation spectra 
are shown with scans of intact precursor ions displayed as insets.  Ion structures with variant 
positions highlighted in red.  Mass error for indicated ions represented as parts-per-million (ppm).  
A) Variant B12 producing 3, has the mutations R235K, W240L, I265L and G291V. B) Variant 
A2 producing 2, has the mutations W240L and G291V.  C) Variant A7 producing 5, has the 
mutations W240S, I254T, G291E.  D) Variant A9 producing 4, has the mutations W240T, I254T, 
G291E.
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 Figure 2.8.  Isotope feeding study to resolve the Ile/Leu ambiguity of clones A2 and B12.  Clones A2 (top panel) and B12 (bottom 
panel) were grown in M9 medium supplemented with 0.1% yeast extract, 0.1% caseaminoacids and 50 mM each 13C2-leucine and 13C6 
isoleucine.  Selected ion chromatograms for m/z 494, m/z 496 and m/z 500 are plotted color coded to the corresponding structure 
indicated.  Both A2 and B12 prefer leucine over isoleucine, but at different levels. 
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 Figure 2.9.  Isotope feeding studies show that either isoleucine or Leucine can be incorporated when supplied in excess.  Clones A2 
(top panel) and B12 (bottom panel) were grown in M9 medium supplemented with 0.1% yeast extract, 0.1% caseaminoacids and 
either no further supplementation, 100 mM 13C2-leucine, or 100 mM 13C2-isoleucine.  Selected ion chromatograms for m/z 494, m/z 
496 and m/z 500 are plotted color coded to the corresponding structure indicated.  Individual feeding experiments show that both 
leucine and isoleucine can be efficiently incorporated into andrimid derivatives when supplemented in the growth medium.
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Figure 2.10. Agar-overlay bioassay of andrimid and analogues generated against E. coli imp 
ASR.  Aliquots of each compound were spotted onto paper disks atop a layer of soft agar seeded 
with E. coli imp ASR. 1, 2, 5, 7 – compounds 1, 4, 5, 7 from Fig. 2.1;  negative control - 50:50 
methanol: water. 
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Table 2.1.   Primers Table 
Oligonucleotides Used 
Primer Sequence 
AdmK-F (NcoI) 
AdmK-R (BamHI) 
AdmK-R (HindIII) 
AdmK-F1 
AdmK-F2 
AdmK-F3 
AdmK-F4 
AdmK-R1 
AdmK-R2 
AdmK-R3 
AdmK-R4 
AdmK-DelFL (BamHI) 
AdmK-DelRL 
AdmK-DelFR  
AdmK-DelRR (NotI) 
AdmKKOF1 
AdmKKOF2 
AdmKKOF3 
AdmKKOF4 
AdmKKOR1 
AdmKKOR2 
AdmKKOR3 
AdmKKOR4 
AdmKShortF 
AdmKShortR 
AdmKLongF 
AdmKLongR 
CatF BglII 
CatR NotI 
rpsL F NotI 
rpsL R XhoI 
3Site1-F 
3Site1-R 
3Site2-F 
3Site2-R 
3Site3-F 
3Site3-R 
 
AATCTGATACCATGGCTGACAAATGGTCAAA 
ATATAAAGGATCCGGCATTGATTTTGTTGGTG 
CTCATCATAAGCTTCTAGGCATTGATTTTGTTGG 
ATACATGACAAATGGTCAAAAACAAGGAG 
GAGTTCTGTGCTCAATTTGCTACATCG 
ACACCGGTGAATACCGAAAATCG 
GATTCCGCCGGACGGTCG 
GCTTTCAGTTTATCTTTGACATTGATAATG 
CCGTCATCCACATGCAGGTTAT 
TTCAACCCGGTGCCCATT 
TAGGCATTGATTTTGTTGGTGACTAAATC 
AAACATAACGGATCCCGGTTGAGCTGTGTC 
GTTGGTGACTAAATCTCTCCTTGTTTTTGACCATTTGTCATGTAT 
CAAGGAGAGATTTAGTCACCAACAAAATCAATGCCTAGATC 
AAAAAAAAGCGGCCGCATTGAATAAACATGC 
CATAACGGATCCCGGTTGA 
AAAACTGAATGGATTCAGAGTCCA 
AAAGACTTCCATACATGACAAATGG 
CGGTGACCGCACTTATGC 
TCATCATCCGATCGTCCAAG 
GTCTCCTGAATGATTTATCTGCG 
GCAAAGATCGACTCGATCGA 
AAAAAAAGCGGCCGCATT 
CATAACGGATCCCGGTTGA 
AAAAAAAAGCGGCCGCAT 
TATGGGCACTCGGTCTACTTGT 
GTACTTATCCAATGCTAACTGGCTG 
AAATTAAAAGATCTTGTTGATACCGGGAAGCC 
AAATTAAAACGCGTTTTAAGGGCACCAATAAC 
AAATATAGCGGCCGCTTAATCCTTTGGCTTCTTC 
CCCCCGACCCCTCGAGAAATCATAAAAAATTT 
CCTGCATGWHKATGACGGCCGG 
CCGGCCGTCATMDWCATGCAGG 
GCACGTCTCAGACATCTAWHWGTCGGTGGAG 
CTCCACCGACWDWTAGATGTCTGAGACGTGC 
CGCAGCTATACAACRHKTACGGGCCG 
CGGCCCGTAMDYGTTGTATAGCTGCG 
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Table 2.2.  Microorganism strains and plasmids. 
 
Strain or plasmid Relevant characteristic 
Escherichia coli 
   DH5α 
    DH5α/λpir 
    BL21(DE3) 
    Imp ASR 
 
F- endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR nupG Φ80dlacZΔM15 Δ(lacZYA-argF)U169, hsdR17(rK- mK+), λ– 
F- endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR nupG Φ80dlacZΔM15 Δ(lacZYA-argF)U169, hsdR17(rK- mK+), λpir 
F– ompT gal dcm lon hsdSB(rB B- mB-) λ(DE3 [lacI lacUV5-T7 gene 1 ind1 sam7 nin5]) 
K-12 derived.  Unknown genotype; imp AmpR, spcR phenotype. 
  
Pantoea agglomerans 
    Eh335 
    PAG rpsL 
    PAGΔK 
    A2 
    A7 
    A9 
    B12 
 
WT environmental isolate 
Eh 335 rpsL 
PAG rpsL, ΔadmK 
PAG rpsL, ΔadmK pQE60 admK W240L, G291V 
PAG rpsL, ΔadmK pQE60 admK W240S, I265T, G291E 
PAG rpsL, ΔadmK pQE60 admK W240T, I265T, G291E 
PAG rpsL, ΔadmK pQE60 admK R235K, W240L, I265L, G291E 
K. pneumoniae ATCC 13883 andrimid sensitive indicator strain 
S. aureus ATCC 25923 andrimid sensitive indicator strain 
E. faecalis ATCC 19433 andrimid sensitive indicator strain 
 Plasmids 
    pQE60 
     pQE60-admK 
     pQE60-admK-His6
     pACYC-Duet 
     pET-28a 
     pET-28aQH admK-His6
     pET-Duet 
     pET-Duet-sfp 
     pET-Duet-sfp-admK-His6
     pUC-19 
     pUC-18 sfp 
     pPAAR 
 
pT5, bla, ColE1 
pT5, bla, ColE1, admK (no His-Tag) 
pT5, bla, ColE1, admK-His6
cat, P15A 
pT7, lacI, ColE1, Kanr 
pET-28a, NcoI/HindIII fragment of  pQE60-admK-His6
pT7, lacI, ColE1, bla 
pT7, lacI, ColE1, bla, sfp in MCSII 
pT7, lacI, ColE1, bla, sfp in MCSII, NcoI/HindIII fragment of  pQE60-admK-His6 in MCSI 
bla, ColE1 
bla, ColE1, sfp 
R6K, OriT, cat, rpsL+ 
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Table 2.3.  Mutations in admK and corresponding products compared with WT production 
levels 
Clone Mutations Compound Produced Medium 
Production per Liter 
(mg) 
WT N/A 1 2xYT 378.16 
4 2xYT + Ile 4.94 A2 W240L, G291V 5 2xYT + Leu 0.99 
4 2xYT + Ile 466.39 B12 R235K, W240L, I265L, G291E 5 2xYT + Leu 93.83 
6 2xYT + Ala 0.19 A7 W240S, I265T, G291E 7 2xYT + Phe 0.36 
6 2xYT + Ala 0.20 A9 W240T, I265T, G291E 7 2xYT + Phe 0.49 
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Table 2.4.  MIC data for andrimid and derivatives against representative Gram 
negative and Gram positive bacterial strains 
 MIC (nmol) 
 1 4 5 
E. coli imp ASR 0.47 2.72 0.73 
K. pneumoniae ATCC 13883 9.05 2.93 NT* 
S. aureus ATCC 25923 7.71 0.39 0.28 
E. faecalis ATCC 19433 36.35 42.76 NT* 
*Not Tested    
 
 
 
 
 54
2.5 References 
 
1. Challis, G.L., Ravel, J., and Townsend, C.A., Predictive, structure-based model of amino 
acid recognition by nonribosomal peptide synthetase adenylation domains. Chem Biol, 
2000. 7(3): p. 211-224. 
2. Rausch, C., Weber, T., Kohlbacher, O., Wohlleben, W., and Huson, D.H., Specificity 
prediction of adenylation domains in nonribosomal peptide synthetases (NRPS) using 
transductive support vector machines (TSVMs). Nucleic Acids Research, 2005. 33(18): p. 
5799-5808. 
3. Stachelhaus, T., Mootz, H.D., and Marahiel, M.A., The specificity-conferring code of 
adenylation domains in nonribosomal peptide synthetases. Chemistry & Biology, 1999. 
6(8): p. 493-505. 
4. Khosla, C., Gokhale, R.S., Jacobsen, J.R., and Cane, D.E., Tolerance and specificity of 
polyketide synthases. Annual Review of Biochemistry, 1999. 68: p. 219-253. 
5. Khosla, C. and Zawada, R.J.X., Generation of polyketide libraries via combinatorial 
biosynthesis. Trends in Biotechnology, 1996. 14(9): p. 335-341. 
6. Tsoi, C.J. and Khosla, C., Combinatorial Biosynthesis of Unnatural Natural-Products - 
the Polyketide Example. Chemistry & Biology, 1995. 2(6): p. 355-362. 
7. Walsh, C.T., Combinatorial biosynthesis of antibiotics: Challenges and opportunities. 
Chembiochem, 2002. 3(2-3): p. 125-134. 
8. Walsh, C.T., O'Connor, S.E., and Schneider, T.L., Polyketide-nonribosomal peptide 
epothilone antitumor agents: the EpoA, B, C subunits. Journal of Industrial Microbiology 
& Biotechnology, 2003. 30(8): p. 448-455. 
9. Shier, W.T., Rinehart, K.L., Jr., and Gottlieb, D., Preparation of four new antibiotics 
from a mutant of Streptomyces fradiae. Proc Natl Acad Sci U S A, 1969. 63(1): p. 198-
204. 
10. Doekel, S. and Marahiel, M.A., Dipeptide formation on engineered hybrid peptide 
synthetases. Chem Biol, 2000. 7(6): p. 373-384. 
11. Mootz, H.D., Schwarzer, D., and Marahiel, M.A., Construction of hybrid peptide 
synthetases by module and domain fusions. Proc Natl Acad Sci U S A, 2000. 97(11): p. 
5848-5853. 
12. Mootz, H.D., Schwarzer, D., and Marahiel, M.A., Ways of assembling complex natural 
products on modular nonribosomal peptide synthetases. Chembiochem, 2002. 3(6): p. 
490-504. 
13. Schneider, A., Stachelhaus, T., and Marahiel, M.A., Targeted alteration of the substrate 
specificity of peptide synthetases by rational module swapping. Mol Gen Genet, 1998. 
257(3): p. 308-318. 
14. Stachelhaus, T. and Marahiel, M.A., Modular structure of peptide synthetases revealed 
by dissection of the multifunctional enzyme GrsA. J Biol Chem, 1995. 270(11): p. 6163-
6169. 
15. Stachelhaus, T. and Marahiel, M.A., Modular structure of genes encoding multifunctional 
peptide synthetases required for non-ribosomal peptide synthesis. FEMS Microbiol Lett, 
1995. 125(1): p. 3-14. 
16. Baltz, R.H., Brian, P., Miao, V., and Wrigley, S.K., Combinatorial biosynthesis of 
lipopeptide antibiotics in Streptomyces roseosporus. J Ind Microbiol Biotechnol, 2006. 
33(2): p. 66-74. 
 55
17. Nguyen, K.T., Ritz, D., Gu, J.Q., Alexander, D., Chu, M., Miao, V., Brian, P., and Baltz, 
R.H., Combinatorial biosynthesis of novel antibiotics related to daptomycin. Proc Natl 
Acad Sci U S A, 2006. 103(46): p. 17462-17467. 
18. Fredenhagen, A., Tamura, S.Y., Kenny, P.T.M., Komura, H., Naya, Y., Nakanishi, K., 
Nishiyama, K., Sugiura, M., and Kita, H., Andrimid, a New Peptide Antibiotic Produced 
by an Intracellular Bacterial Symbiont Isolated from a Brown Planthopper. Journal of 
the American Chemical Society, 1987. 109(14): p. 4409-4411. 
19. Jin, M., Fischbach, M.A., and Clardy, J., A biosynthetic gene cluster for the acetyl-CoA 
carboxylase inhibitor andrimid. J Am Chem Soc, 2006. 128(33): p. 10660-10661. 
20. Singh, M.P., Mroczenski-Wildey, M.J., Steinberg, D.A., Andersen, R.J., Maiese, W.M., 
and Greenstein, M., Biological activity and mechanistic studies of andrimid. J Antibiot 
(Tokyo), 1997. 50(3): p. 270-273. 
21. Freiberg, C., Brunner, N.A., Schiffer, G., Lampe, T., Pohlmann, J., Brands, M., Raabe, 
M., Habich, D., and Ziegelbauer, K., Identification and characterization of the first class 
of potent bacterial acetyl-CoA carboxylase inhibitors with antibacterial activity. J Biol 
Chem, 2004. 279(25): p. 26066-26073. 
22. Freiberg, C., Pohlmann, J., Nell, P.G., Endermann, R., Schuhmacher, J., Newton, B., 
Otteneder, M., Lampe, T., Habich, D., and Ziegelbauer, K., Novel bacterial acetyl 
coenzyme A carboxylase inhibitors with antibiotic efficacy in vivo. Antimicrob Agents 
Chemother, 2006. 50(8): p. 2707-2712. 
23. Belshaw, P.J., Walsh, C.T., and Stachelhaus, T., Aminoacyl-CoAs as probes of 
condensation domain selectivity in nonribosomal peptide synthesis. Science, 1999. 
284(5413): p. 486-489. 
24. Fischbach, M.A., Lai, J.R., Roche, E.D., Walsh, C.T., and Liu, D.R., Directed evolution 
can rapidly improve the activity of chimeric assembly-line enzymes. Proceedings of the 
National Academy of Sciences of the United States of America, 2007. 104(29): p. 11951-
11956. 
25. Vanneste, J.L.V., M. D., Characterization of transposon, genes, and mutations which 
confer streptomycin resistance in bacterial strains isolated from New Zealand orchards. 
Acta Horticulturae, 2002. 590(Proceedings of the IXth International Workshop on Fire 
Blight, 2001): p. 493-495. 
26. Shanks, R.M.Q., G.A. O'Toole. http://www.dartmouth.edu/~gotoole/vectors.html. 
27. Thompson, J.D., Gibson, T.J., Plewniak, F., Jeanmougin, F., and Higgins, D.G., The 
CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment 
aided by quality analysis tools. Nucleic Acids Res, 1997. 25(24): p. 4876-4882. 
28. Russell, C.B. and Dahlquist, F.W., Exchange of chromosomal and plasmid alleles in 
Escherichia coli by selection for loss of a dominant antibiotic sensitivity marker. J 
Bacteriol, 1989. 171(5): p. 2614-2618. 
29. Horton, R.M., In vitro recombination and mutagenesis of DNA. SOEing together tailor-
made genes. Methods Mol Biol, 1997. 67: p. 141-149. 
30. Sarkar, G. and Sommer, S.S., The "megaprimer" method of site-directed mutagenesis. 
Biotechniques, 1990. 8(4): p. 404-407. 
31. Patrick, W.M., Firth, A.E., and Blackburn, J.M., User-friendly algorithms for estimating 
completeness and diversity in randomized protein-encoding libraries. Protein Eng, 2003. 
16(6): p. 451-457. 
 56
32. Crameri, A., Raillard, S.A., Bermudez, E., and Stemmer, W.P., DNA shuffling of a family 
of genes from diverse species accelerates directed evolution. Nature, 1998. 391(6664): p. 
288-291. 
 
 
 57
CHAPTER 3 
DEVELOPMENT AND INITIAL APPLICATION OF A PROTEOMICS BASED 
APPROACH TO NATURAL PRODUCTS DISCOVERY 
 
The information and contents of this chapter were taken from the following article with 
permission from the publisher: Stefanie B. Bumpus, Bradley S. Evans, Paul M. Thomas, 
Ioanna Ntai and Neil L. Kelleher (2009). “A proteomics approach to discovery of natural 
products and their biosynthetic pathways.” Nature Biotechnology, 27(10):951-956.  This 
first successful implementation of proteomics as a natural products discovery tool was 
greatly accelerated by the help of Stefanie B. Bumpus and Paul M. Thomas.  Paul 
Thomas prepared and analyzed proteomic samples; Stefanie Bumpus prepared and 
analyzed metabolomic samples.  Bradley Evans isolated microorganisms, developed 
SDS-PAGE based screening methods, identified high-molecular weight protein 
producing strains, developed in-gel trypsin digestion/ nanoLC-MS/MS methods, designed 
degenerate primers and performed bioinformatics analyses. 
 
3.1 Background 
The natural product discovery process has diverse implementations, and the 
strategies for discovery continue to evolve as more microbial genomes become available.  
Traditional discovery platforms employ a bioassay-guided strategy, where an iterative 
cycle of metabolite fractionation and bioassay panels attempt to isolate the single small 
molecule responsible for the observed bioactivity[1].  This process rediscovers known 
compounds most of the time, highlighting the inefficiency of this “dereplication” 
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bottleneck.  The purpose of development of the complementary platform presented here 
is to circumvent some of the limitations of bioassay based screening, most critically the 
bias that arises when screening for only one drug target or indicator cell line.  Described 
in this chapter is a process that allows detection of all natural products produced and 
targeted characterization of those produced by NRPS and PKS.   
There have been a few successful attempts at using genome sequence information 
to predict production of a natural product [2-4].  There is, however, a great disparity 
between the genetic capacity for natural product production and the actual expression of 
biosynthetic gene clusters under laboratory culture conditions.    The therapeutic value of 
NRPS and PKS products combined with the lack of methods to detect expressed 
NRPS/PKS gene clusters in discovery mode prompted development of a general 
approach, PrISM (for the Proteomic Investigation of Secondary Metabolism), based on 
microbial proteomics.  PrISM is not reliant on availability and analysis of genome 
sequence and instead targets those gene clusters expressed into protein.  Proteomics 
offers an orthogonal approach to genomics or metabolomics that can simultaneously 
detect enzymes of secondary metabolic pathways and direct the search for the 
corresponding natural product.   
 
3.2 Experimental Procedures 
Analysis of model proteomes. Complete protein coding sequences of B. subtilis 
168, S. coelicolor A3(2) and M. xanthus DK1622 were downloaded from the Integrated 
Microbial Genome website (http://img.jgi.doe.gov).  Proteome summary data were 
exported to a tab delimited file and analyzed using Microsoft Excel.   
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 Assay Development of a Model System, the gramicidin synthetases of B. brevis. B. 
brevis proteomes were prepared on 1 L scale in YP + NaCl medium (per L: 9 g peptone, 
5 g yeast extract, 5 g NaCl (pH 7.2–7.25)) inoculated with a 10 mL of an overnight B. 
brevis culture, and grown for 8 hours.  The culture was harvested by centrifugation and 
the cell pellet was resuspended in SDS-PAGE loading buffer.  The proteome was 
analyzed as described below.  
 
 Isolation of Bacilli and preparation of proteome samples.  Soil was collected 
from Haughton, LA, USA and bacillus strains were isolated by heat treatment and 
dilution plating on nutrient agar [5].   For SDS-PAGE screening, 5 mL cultures were 
grown in the appropriate medium and 1 mL samples were collected at predetermined 
interval.  The medium was removed by centrifugation and the pellet was resuspended in 
SDS-PAGE loading buffer and stored at - 20º C until analyzed.  For proteomic analysis 
by in-gel trypsin digestion followed by nanoLC-MS/MS, a 1mL overnight starter culture 
of NE3-4 in nutrient broth used to inoculate 100 mL nutrient broth.  The 100 mL culture 
was grown at 30º C and 250 rpm. The culture was collected at 24 h.  Cells were harvested 
by centrifugation (5,000 rpm, 5 min) and resuspended in a minimal amount of SDS-
PAGE loading buffer, boiled, vortexed, then centrifuged to remove insoluble material.  
The supernatant was then stored at -20 º C until needed.  
 
 Genetic Analysis of Bacillus Isolates. Genomic DNA was isolated from bacillus 
isolates starting from a 5 mL LB overnight culture using a Qiagen DNeasy DNA 
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extraction kit.  PCR was performed using Promega GoTaq 2X mix to amplify 16SrDNA.  
The 16SrDNA was sequenced for genetic dereplication.  16SrDNA sequences were used 
to construct a phylogenetic tree using the software package MEGA4 [6].   
 
 Gel-based proteomic analysis.  An aliquot of the proteome (1-300 µL) incubated 
at 95°C for 5 min before loading onto an SDS-PAGE gel (Tris-HCl 4/10%T, preparative 
well with one reference well).  The gel was stained with colloidal Coomassie blue G-250 
and the bands were excised with a razor blade and cut into 1 mm3 pieces.  These gel 
samples were then destained, reduced with DTT, alkylated with iodoacetamide and 
digested with trypsin[7, 8].  Peptides were extracted, lyophilized, rehydrated with 0.1% 
acetic acid and bomb-loaded onto a self-packed C4 nano-LC guard column (75µ x 10 cm, 
10-20 µm particle size).  This guard column was then placed upstream of a ProteoPepII 
C18 column (75 µ x 10 cm, New Objective) and peptides were eluted over an 90 min 
linear gradient of water and acetonitrile with 0.1 % formic acid at a flow rate of 300 
nL/min (produced by an Eksigent 1D nano-LC) into a 12T ThermoFisher LTQ-FT Ultra.  
Samples were analyzed using the online Ppant ejection assay as well as data-dependent 
low resolution CID on the top six precursors.  LC-MS/MS data from each in-gel 
digestion run were processed into DTA files with BioWorks 3.2 (ThermoFisher, San Jose, 
CA) and concatenated into encapsulated XML.  These data were automatically searched 
against the nr protein database with OMSSA [9] using standard settings for the detection 
of intact peptides at high resolution (FTMS) and MS/MS fragment ions with unit 
resolution (ITMS) (0.01 Da intact peptide tolerance, 0.5 Da fragment ion tolerance).  
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Individual files were then combined into one master file for viewing with the OMSSA 
browser. 
 
 Primer design and PCR.  Peptide sequences were reverse translated using the 
web-based Reverse Translate Tool (http://www.bioinformatics.org/sms2/rev_trans.html) 
using the B. cereus ATCC 10987 codon usage table.  This program returns two sets of 
DNA sequences, the most likely based on codon usage frequencies and a degenerate set 
that accounts for any instances of multiple base use for a particular codon.  Both the most 
likely and highly degenerate reverse translations were used to design primers.  All 
primers were used for PCRs with NE3-4 gDNA as template.  Genomic DNA was isolated 
from a 5 mL LB overnight culture using a Qiagen DNeasy DNA extraction kit.  PCR was 
performed using Promega GoTaq 2X mix or recombinant Taq prepared by the Meatcalf 
lab. 
 
DNA Sequencing:  PCR products were analyzed by agarose gel electrophoresis 
and bands of interest were excised, purified using a Qiagen gel extraction kit.  Purified 
bands were quantified by agarose gel electrophoresis and sequenced using amplification 
primers and ABI BigDye 3.1 terminators.  Sequencing reactions were analyzed at the 
UIUC DNA core facility on an ABI 3730XL capillary sequencer and the data were 
analyzed using Gene Code Sequencer software.  
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 3.3 Results and Discussion 
  Analysis of three model bacterial proteomes, Bacillus subtilis 168, Streptomyces 
coelicolor A3(2) and Myxococcus xanthus DK 1622 show that of 16,579 proteins, only 
63 are NRPSs or PKSs (0.38%).  When the 16,579 proteins are sorted into bins of amino 
acid length, it becomes apparent that NRPS and PKS enzymes make up the bulk of high 
molecular weight proteins (HMWPs) (Fig. 3.1)  Although NRPS and PKS enzymes 
constitute a small fraction of overall proteomes, their uncommonly large size allows for 
screening and pre-fractionation of proteomes using SDS-PAGE.  HMWP bands indicate 
the likely presence of NRPS and/or PKS enzymes.  These HMWP bands can then 
analyzed by in-gel proteolysis and nanoLC-MS/MS.  The resulting sequence 
accomplishes dereplication and can then used in the construction of oligonucleotide 
probes with which the genome of the organism can be interrogated and associated DNA 
cloned and sequenced.  Partial or full DNA sequence can then guide the search for new 
natural products based upon the co-linearity rules of NRPS and PKS biosynthesis.  PrISM 
extends our knowledge well beyond the genetic capacity of an organism to produce 
secondary metabolites by temporally linking gene expression and small molecule 
production.  RNA level analyses can not provide similar information, as they require 
prior DNA sequence. 
 The most famous and most often exploited bacterial genus with respect to natural 
products is the genus streptomyces, which produces two-thirds of the known antibiotics 
produced by microorganisms [10].  Initial experiments performed on streptomycete 
proteomes frustrated attempts to implement a proteomic method.  This was in part due to 
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the complex life cycle and slow generation time for this genus, and also due to 
complicating factors such as apoptosis-like programmed cell death that leads to a large 
portion of the biomass of a streptomyces culture to be non-vegetative [11].  For this 
reason the genus bacillus was chosen for development of PrISM.  Bacilli are another 
genus that are prolific natural product producers.  B. subtilis, for example is known to 
produce more than two dozen antibiotics [12].  In addition to being a validated source for 
natural products, bacilli are easily isolated from the environment, have a short generation 
time, and importantly, it was found protein extraction from these organisms is facile.  For 
initial development, B. brevis ATCC 9999, the producer of the nonribosomal peptide 
gramicidin S was selected.  The NRPSs of the gramicidin S pathway are well 
characterized and represent a model NRPS system [13-16].  For the reasons above, the 
gramicidin S system was chosen for assay development.  Cultures of B. brevis were 
harvested and analyzed by SDS-PAGE followed by in-gel trypsin digestion and nanoLC-
MS/MS; the results are summarized in Table 3.1.  The results of the B. brevis study show 
selective and unambiguous detection of both NRPSs of the gramicidin S pathway.  
Having demonstrated the utility of SDS-PAGE screening of bacterial proteomes coupled 
to nanoLC-MS/MS for the selective detection of NRPSs, this proteomics approach was 
applied to strains isolated from the environment without the benefit of DNA sequence or 
other information a priori.  Soil samples collected from Haughton, LA were used for 
isolation of 23 bacilli.  The isolates were taxonomically dereplicated using 16S rDNA 
analysis.  A phylogenetic tree of the bacillus isolates along with in- and out- groups are 
shown in Fig. 3.2.   
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SDS-PAGE was used as an initial screen for these 23 strains, each grown for 2 
days at 30oC in nine different growth media with sampling at 8, 16, 24, 36 and 48 h.  The 
media selected for screening were nutrient broth, M17 broth, Mueller-Hinton broth and 
six minimal media:  sucrose minimal medium (SMM), sucrose minimal medium lacking 
phosphate (SMM –P), sucrose minimal medium lacking iron (SMM –Fe), mannitol 
minimal medium (MMM), glycerol minimal medium (GMM) and starch minimal 
medium (starch MM).  Minimal media compositions are listed in Table 3.2.  Twenty of 
the 23 strains showed expression of high molecular weight proteins (HMWPs) (indicative 
of NRPS/PKS expression) for at least one time point (Table 3.3), including the strain, 
NE3-4, which was subjected to full proteome analysis and nanoLC-MS of in-gel digests 
of HMWPs (Fig. 3.3).     
   Peptides identified (Table 3.4) by OMSSA searching of nanoLC-MS/MS data 
as coming from NRPSs were examined for instances where >6 contiguous amino acids 
were sequenced.  Peptides in this category are suitable for use in designing PCR primers. 
These relatively long amino acid sequences give at least 18 bp primer sequences and 
therefore increase the probability of annealing of primers to the DNA template.  This is of 
special concern when degenerate primers are used because of likely incomplete matching 
of probe to the gDNA.  Primers designed from peptides identified by OMSSA are listed 
in Table 3.5.  For the NE3-4 data set, there were multiple peptide matches to B. cereus 
AH1134 NRPSs.  Multiple peptide hits per protein allowed for PCRs to be set up to 
amplify DNA regions corresponding to amino acid sequences between identified peptides.  
Additionally, because of the multiple peptide matches it seemed likely that strain NE3-4 
did in fact have very similar gene clusters to B. cereus AH1134.  In order to test this 
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hypothesis, primers were designed based off of the B. cereus AH1134 gDNA sequence.  
Fig. 3.4 shows the results of 11 representative PCR reactions; these and other PCRs were 
sequenced demonstrating that PrISM provides ample microsequence to convert peptide 
MS/MS data into DNA sequence of expressed NRPS/PKS gene clusters.  Sequencing 
results showed that the NE3-4 sequences bear >97% identity to the B. cereus AH1134 
sequences; the results are summarized in Table 3.6.    
 After integrated MS/MS and DNA sequencing analysis it was apparent that the 
peptides identified arose from expression of two separate gene clusters, labeled here as 
cluster #1 (C1) and cluster #2 (C2), coming from at least three different NRPS/PKS 
synthases (C1S2 (ZmaA), C1S6 (ZmaK) and C2S2) on two separate contigs (C1 from 
contig GenBank accession number ABDA02000035 and C2 from contig Gen Bank 
accession number ABDA02000007).  The high sequence identity between strain NE3-4 
and B. cereus AH1134 at both the DNA and protein levels suggested that the biosynthetic 
pathways were essentially identical.  Further analysis was therefore performed using the 
B. cereus AH1134 translated nucleotide sequences. 
 A large number of the genes in cluster #1 are homologous to those that produce 
the aminopolyol antibiotic, zwittermicin A.  Zwittermicin A has a broad spectrum of 
activity against both Gram-positive and Gram-negative bacteria as well as certain 
eukaryotes[17].  A total synthesis was recently reported[18] and the sequence of 
individual biosynthetic proteins has been reported over the past four years[19].  A 2009 
report based on the analogous B. cereus AH1134 sequence found to be expressed in NE3-
4 revealed that the Zma biosynthetic gene cluster is much larger than expected and 
predicted to produce three Zma-related compounds[19].  Targeted searching for such 
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molecules allowed detection of zwittermicin A and a previously undetected methionine-
containing NRPS product, thus completing the PrISM approach[20].   
 Evidence for expression of a second cluster from bacillus strain NE3-4 was 
uncovered by detection of peptides from the two-module NRPS protein depicted as C2S2 
in Fig. 3.5.  Annotation of the flanking ~30 kb of sequence from B. cereus AH1134 
around the gene for the protein identified from this cluster is shown in Fig. 3.6. Three 
NRPSs are present in this gene cluster, along with a nearby efflux protein, 
phosphopantetheinyl transferase and type II thioesterase.  There are homologs of this 
gene cluster known in other B. cereus strains such as B4264 and G9842, and multiple B. 
weihenstephanensis strains, but it is clearly an orphan with no corresponding natural 
product known. Domain structure for the NRPSs were predicted using a BLAST 
conserved domain search of the NRPS sequences [21].  Adenylation domain substrate 
specificity was predicted using NRPSpredictor [22].   A peptide with amino acids 
including serine (Ser), alanine (Ala) and threonine (Thr), and two glutamine (Gln) or 
glutamate (Glu) residues at the C-terminus was predicted to be the product of cluster 2.  
This information was used to direct the search for the natural product. 
    Targeted analysis of NE3-4 extracts for peptides matching predictions made from 
amino acid sequences of the adenylation domains uncovered a set of six related species at 
m/z 908.4845, 922.5007, 926.4951, 936.5165, 940.5112, and 954.5272 that were 
analyzed and sequenced using MS/MS and determined to be new kurstakin family 
members [20] a representative kurstakin is shown in Figure 3.5 . 
 One could point to some potential disadvantages of using proteomics as an entrée 
to natural products discovery.  From the standpoint of practitioners of small-molecule 
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based approaches such as bioactivity guided screening, the information obtained by 
monitoring expression of secondary metabolic enzymes via proteomics is superfluous; if 
a metabolite is being produced that is detectable by the screening method, it will be 
detected.  This is true; however, approaches such as this suffer from selectivity issues.  
Bioactivity guided screening has a tunnel vision-like purpose of finding an agent that 
causes a response to a particular biological target.  While bioactivity guided screening has 
been a reliable method for discovering new bioactive molecules, many that are active 
against targets other than the one used in the screen are missed.   By changing the focus 
to finding new natural products regardless of bioactivity the process moves toward a 
more all encompassing approach with respect to detection of natural products.  From the 
standpoint of genome miners, detection of pathways expressed under laboratory 
conditions is not enough.  PrISM certainly does not take on the challenge of exploiting 
the vast wealth of cryptic gene clusters; that is a fact.  PrISM does, however offer a 
complementary approach that does quickly screen for and identify expressed gene 
clusters.  At this point, no general methods for inducing cryptic gene clusters exist and no 
one can say for sure if such methods will be developed.  Until such methods are 
developed, PrISM provides a way to access and exploit the many secondary metabolic 
pathways expressed by microbes without the benefit of having genome sequence to guide 
natural product discovery.  Another limitation of PrISM is self-imposed; the method as 
presented here detects only NRPS and PKS pathways, and only those that are composed 
of HMWPs.  NRPS and PKS pathways whose enzymes are in the mid-range of 
proteomes (50-100 kDa) will go undetected as will pathways the biosynthesize other 
natural product classes such as aminoglycosides and terpenes. 
  68
Limitations aside, PrISM has proven successful as a natural product discovery 
tool.  Combining DNA sequence information (obtained after proteome analysis) with the 
rules of co-linear biosynthesis catalyzed by NRPSs and PKSs, one can predict specific 
structural features of the NRP or PK natural product (including whether the scaffold is 
novel).  This targets detection efforts and informs natural product discovery pipelines in a 
new way; dereplication is achieved at the biopolymer-level, not the small molecule-level.  
Thus, a reversal from the common approach to natural product discovery is now possible 
that positions proteomics as an early stage screen, with subsequent small molecule 
detection modalities (e.g., bioassays, MS, or NMR) then brought in for a great variety of 
conditions to assess activity after the scaffold and NP is shown to be novel, ameliorating 
some aspects of the dereplication bottleneck[23]. Future efforts will realize efficiencies of 
scale to detect enzyme fingerprints from strains cultured on plates, from unsequenced 
fungi, and even to complex marine microorganism-invertebrate assemblages[24], with 
extension of the approach to all types of secondary metabolism also possible. 
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3.4 Figures and Tables 
 
Figure 3.1.  Distribution of NRPS/PKS proteins across protein length bins.  The protein coding sequences of B. subtilis, S. coelicolor 
and M. xanthus were downloaded from the Integrated Microbial Genomes website, sorted into 500 amino acid length bins and 
separated into NRPS/PKS proteins and non NRPS/PKS proteins.  Bins 1000-1500, 500-1000 and 19-500 have too many proteins for 
the top of the graph to be displayed; fraction of NRPS/PKS proteins out of all proteins are represent as fractions for these bins.  The 
data were graphed in Microsoft Excel. 
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Table 3.1.  Peptides identified from GrsA and GrsB in B. brevis by nanoLC-MS 
Protein Sequencea AA Rangeb -log Ec
GrsA  417-428 4 
    
GrsB  94-103 7 
GrsB  541-554 2 
GrsB  685-695 8 
GrsB  696-709 4 
GrsB  955-968 6 
GrsB  1048-1069 8 
GrsB  1579-1594 1 
GrsB  1831-1852 4 
GrsB  1885-1896 2 
GrsB  1908-1919 6 
GrsB  2015-2027 3 
GrsB  2513-2526 5 
GrsB  2527-2542 5 
GrsB  2745-2760 6 
GrsB  3035-3053 6 
GrsB  3536-3549 3 
GrsB  3661-3676 3 
a Peptide sequence from B. brevis ATCC 9999 with the matching b and y fragments illustrated as left and right flags, 
respectively. 
b Amino acids matched in the parent protein. 
c OMSSA expectation score for the peptide [9] 
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 Figure 3.2. Neighbor-joining phylogenetic tree constructed with MEGA5 from 16S 
rDNA sequences of bacillus isolates and in- and out-groups.  Bootstrap values shown. 
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Table 3.2.  Culture Media for Proteome Screening 
 Medium 
Component SMM SMM -P SMM -Fe GMM MMM Starch MM 
K2HPO4 .25 % N/A .25 % .25 % .25 % .25 % 
KH2PO4 .25 % N/A .25 % .25 % .25 % .25 % 
(NH4)2SO4 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 
MgSO4 7H2O 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 
FeSO4 7H2O 0.001% 0.001% N/A 0.001% 0.001% 0.001% 
MnSO4 H2O 0.015% 0.015% 0.015% 0.015% 0.015% 0.015% 
caseamino acids 0.05% 0.05% 0.05% 0.05% 0.05% 0.05% 
yeast extract 0.05% 0.05% 0.05% 0.05% 0.05% 0.05% 
sucrose 1% 1% 1% N/A N/A N/A 
glycerol N/A N/A N/A 1% N/A N/A 
mannitol N/A N/A N/A N/A 1% N/A 
soluble starch N/A N/A N/A N/A N/A 1% 
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Table 3.3.  Summarized Results from HMWP Screening of Bacillus Isolates by SDS-PAGE 
Medium (Time-point Indicated)
 Rich Media Minimal-Semi-Defined Media 
 M17 NB MHB SMM Starch MM GMM MMM SMM -Fe SMM -P 
NE1-1   16-48 h    36 & 48 h   
NE1-2    36 & 48 h   36 & 48 h 36 & 48 h  
NE2-1          
NE2-2   8-48 h 36 & 48 h   36 & 48 h   
NE2-3          
NE2-4      24-48 h    
NE3-1    8-48 h  36 & 48 h 24-48 h   
NE3-2   48 h 24-48 h  24-48 h 24-48 h 36 & 48 h  
NE3-4  24 h 36 h   24-48 h    
NW1-3      24 & 36 h  24-48 h  
NW2-1          
NW2-2        24-48 h 24-48 h 
NW2-3          
NW2-4     48 h  36 & 48 h  36 & 48 h 
NW3-1          
NW3-2    24-48 h    24-48 h  
NW3-3    16-48 h 36 & 48 h 24 & 36 h  48 h 48 h 
NW3-4     36 & 48 h   24-48 h  
SC1-2  8 h  16-48 h 24 h  16-48 h   
SC1-3   8-48 h 16-48 h 48 h  16-48 h  24 & 36 h 
SC2-2   48 h    36 & 48 h  48 h 
SC3-3          
NE1-1   16-48 h    36 & 48 h   
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 Figure 3.3.  SDS-PAGE Analysis of NE3-4 Proteome.  Highlighted region was excised 
and subjected to in-gel trypsin digestion followed by nanoLC-MS/MS. 
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Table 3.4.  Peptides identified from C1S2 (ZmaA), C1S6 (ZmaK) and C2S2 during 
nanoLC-MS.   
 
Cluster/Protein Sequencea AA Rangeb -log Ec
C1S2  1000-1016 11 
C1S2  1231-1253 12 
C1S2  1386-1400 7 
C1S2  1716-1732 8 
C1S2  1780-1801 12 
C1S2  2201-2218 10 
C1S2  2275-2288 8 
C1S2  2327-2338 5 
C1S2  2420-2438 9 
C1S2  2499-2513 7 
C2S6  55-64 2 
C2S6  187-205 13 
C2S6  256-269 6 
C2S6  937-956 16 
C2S6  1056-1069 8 
C2S6  1162-1182 12 
C2S6  1376-1392 6 
C2S6  1424-1436 3 
C2S6  1495-1510 6 
C2S6  1519-1532 8 
C2S6  1614-1630 2 
C2S6  1748-1764 11 
C2S6  1814-1832 15 
C2S2  250-266 8 
C2S2  306-317 7 
C2S2  851-862 3 
C2S2  874-885 8 
C2S2  906-920 9 
C2S2  1344-1359 9 
C2S2  1611-1621 6 
C2S2  1849-1867 13 
C2S2  1923-1934 7 
a Peptide sequence from B. cereus AH1134 with the matching b and y fragments illustrated as left and right flags, 
respectively. 
b Amino acids matched in the parent protein. 
c OMSSA expectation score for the peptide [9]. 
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Table 3.5.  Primers designed for PCR analysis of the NE3-4 genome.   
 
Primer Sequence 
C1S2-1-F ATGAAGCATCAAGATGATAGTAAAA 
C1S2-1-R TTAGGATCTACATCCTTAACTTGTGT 
C1S2-2-F GGAAGGAGTTTATTTAATTACTGGTG 
C1S2-2-R CACTTGCCAATATAAGTTAGGAGAT 
C1S2-3-F ATGAAGCAAATGTAGAACCTGA 
C1S2-3-R CTTGTATTGTCCCTATTCAACTCTT 
C1S2-4-F ATTTTTGTGTTCTAATGTCTTCAATT 
C1S2-4-R CCTATAATATCTTGTAAATCCGCA 
ZmaR-F ATGATTTATGAATTGGTAAAAGAAAAG 
ZmaR-R TCATCTTAAGCTATCTTCAACTCTATC 
C1S6-1-F ATGAGGAAAGCAGTAAAGATTCA 
C1S6-1-R ATCCAACATTACAGCTACTGGC 
C1S6-2-F CTTCTAATACATTAGAAGATTTCCAAG 
C1S6-2-R AAATGTAATGCATCTTCATAAGAC 
C1S6-3-F AATGCATTATGAAATGCTATTTT 
C1S6-3-R ATTAATACGAACAAGATCTAAAGAACT 
C2S2-Deg-F YTWAAYACDYTNGTNCAAGGNG 
C2S2-Deg-R GCRAARAANCCDATNAR 
C2S2-NonDeg-F TTAAATACATTAGTACAAGGAG 
C2S2-NonDeg-R GCAAAAAATCCAATTAA 
C2S2-NonDeg-F-long GGAAATACAGAAGAATGG 
C2S2-DegF-long GGNAAYACNGARGARTGG 
C2S2-NonDeg-R-long CCATTCTTCTGTATTTCC 
C2S2-DegR-long CCAYTCYTCNGTRTTNCC 
C2S2-1-F TCATTTTTTTACCCCTTCCT 
C2S2-1-R GTATGCACGAGTGAAGTGAC 
C2S2-2-F CATTTTGGATAAGAGGCAATTT 
C2S2-2-R TTGGCATTCAGGATTCCT 
C2S2-3-F CATCAAATGAGAATGGCGT 
C2S2-3-R AGTGAAGTGATGGAAGTTTATCTCA 
C1S6-1-NonDeg-F CCATGGAAAGAAGAAGTA 
C1S6-1-NonDeg-R ATCTAATACTTCATCCATCAT 
C1S6-1-Deg-F CCNTGGAARGARGARGTN 
C1S6-1-Deg-R RTCNARNACYTCRTCCATCAT 
C1S2-1-Nondeg-F GTAAATGAATTTTGGAATAAT 
C1S2-1-Nondeg-R CCATTGTGGTGTATAAAA 
C1S2-1-Deg-F GTNAAYGARTTYTGGAAYAAY 
C1S2-1-Deg-R CCAYTGNGGNGTRTARAA 
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 Figure 3.4.  Representative PCRs.  A. Gel #1, PCRs 1-6.  B.  Gel #2, PCRs 7-11.  C.  
Legend for PCRs.  M – 1kb ladder. 
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Table 3.6.  Summary of Sequencing Results.   
 
Cluster #1 
Primer Read Length (bp) Number of 
Mismatches to 
AH1134 
% Identity to 
AH1134 
C1S2-1-F 640 11 98.3 
C1S2-1-R 799 22 97.2 
C1S2-2-F 640 10 98.4 
C1S2-2-R 720 13 98.2 
ZmaR-F 601 6 99.0 
ZmaR-R 720 10 98.6 
C1S2-1-Deg-R 719 17 97.6 
C1S6-1-NonDeg-F 719 17 97.6 
C1S6-1-NonDeg-R 719 17 97.6 
C1S6-1-Deg-F 293 3 98.9 
 
Cluster #2 
Primer Read Length (bp) Number of 
Mismatches to 
AH1134 
% Identity to 
AH1134 
C2S2-3-F 720 4 99.4 
C2S2-3-R 320 1 99.6 
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 Figure 3.5.   Domain organization of cluster #2 based upon the gene sequence in B. cereus AH1134 and structure of a representative 
kurstakin.  Amino acid substrates were selected based upon bioinformatic analysis and the structure of the detected peptides.    
Abbreviations:  C – condensation domain, A – adenylation domain, T – thiolation domain, TE – thioesterase, PPTase – 
phosphopantetheinyl transferase. 
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Figure 3.6.  ORF map for kurstakin cluster
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CHAPTER 4 
DISCOVERY OF A NOVEL NONRIBOSOMAL PEPTIDE, SEQUENCING AND 
ANALYSIS OF ITS BIOSYNTHETIC GENE CLUSTER 
 
  
 
4.1 Background 
 
  In the previous chapter the approach called PrISM (Proteomic Investigation of 
Secondary Metabolism)[1] was described.  PrISM, rather than attempting to force 
expression of secondary metabolite gene clusters discovered by genome mining, mines 
microbial proteomes to discover expressed gene clusters.  In this chapter the discovery of 
a novel nonribosomal peptide and its corresponding biosynthetic gene cluster is reported.   
 Given the diverse and important biological activities of nonribosomal peptides, 
considerable research efforts have been invested in their discovery, and synthesis as well 
as biosynthetic elucidation and re-engineering.    Following an initial report of a new 
proteomics-based method to discover natural products made via NRPSs and polyketide 
synthases (PKSs), this chapter describes discovery of a novel nonribosomal peptide 
(NRP) scaffold.  PrISM offers several advantages; the screening method employed is 
simple and scalable to high-throughput applications allowing researchers to sample many 
strains and culture conditions in parallel, having the genome sequence of the strains under 
examination is not a pre-requisite and pathways that are recalcitrant to induced 
expression are avoided.    
4.2 Experimental procedures 
Chemicals, media and reagents:  All chemicals were from Sigma (St. Louis, MO) 
unless otherwise noted.  Restriction enzymes, DNA ligase and DNA polymerase 
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(Finnzymes’ Phusion for cloning and NEB’s Thermo Pol for routine PCR) were from 
New England Biolabs (Ipswich, MA).  Growth media were from BD Biosciences (San 
Jose, CA).  Oligonucleotides were purchased from Integrated DNA Technologies 
(Coralville, IA) and listed in Table 4.1.  SDS-PAGE and agarose gel supplies were from 
Bio-Rad (Hercules, CA).  PCR cleanup, plasmid miniprep and gel extraction kits were 
from Qiagen (Valencia, CA).  Stable-isotope labeled amino acids were from Cambridge 
Isotopes (Andover, MA)  Antibiotics were used at the following concentrations unless 
otherwise specified:  ampicillin 100 μg/mL, kannamycin μg/mL, chloramphenicol 12.5 
μg/mL, spectinomycin 100 μg/mL. 
Microorganisms:  Bacilli were isolated as previously described[1].  E. coli DH5α 
λpir and WM 4489 were a gift for William Metcalf.  B. subtilis 168 was a gift from 
George Ordal.  Saccromyces cerevisiae HZ 848 was a gift from Huimin Zhao. 
 Plasmids:  Fosmid pJK0050 was a gift from William Metcalf.  Plasmid pBEX 
was constructed by PCR from pQE60 (Qiagen), pET-Duet (Novagen), pMQ118 (Presque 
Isle Cultures) pQE60-EGFP (unpublished) and pAIN750 (a gift from George Ordal).  
Left-side vector flanking sequence was amplified from pQE-60 with primers pQE60-F 
and pQE60-‘amyE-R to give PCR product pQE-60 spacer-F. ‘amyE was amplified from 
pAIN750 using primers pQE60-‘amyE-F and ‘amyE-LacI-R to give PCR product ’amyE.  
LacI was amplified from pET-Duet using primers ‘amyE-LacI-F and LacI-GFP-R to give 
PCR product LacI.  pT5-EGFP-His6 was amplified from pQE60-EGFP using primers 
LacI-GFP-F and GFP-spc-amyE’-R to give PCR product GFP. Spc-amyE’ was amplified 
from pAIN 750 using primers GFP-spc-amyE’-F and Spc-amyE’-Cen-R to give PCR 
product spc-amyE’.  Cen/ARS-URA3 was amplified from pMQ118 using primers Spc-
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amyE’-Cen-F and Cen-pQE60-R to give PCR product Cen/ARS-URA3.  Right-side 
vector flanking sequence was amplified from pQE-60 using primers Cen-pQE60-F and 
pQE60-R to give PCR product pQE60 spacer-R.  PCR products from the above reactions 
were gel purified using standard procedures.  Fragment pQE60-‘amyE-LacI was 
constructed by OE-PCR using PCR products pQE60 spacer-F, ‘amyE and LacI in a three 
way OE extension reaction, followed by a final amplification using pQE-60-F and LacI-
GFP-R.  Fragment LacI-GFP was constructed by OE-PCR using PCR products LacI and 
GFP in an extension reaction followed by final amplification using primers ‘amyE-LacI-
F and GFP-spc-amyE’-R.  Fragment GFP-Spc-amyE’ was constructed by OE-PCR using 
PCR products GFP and spc-amyE’ in an extension reaction followed by final 
amplification using primers LacI-GFP-F and Spc-amyE-Cen-R.  Fragment Spc-amyE’-
Cen/ARS-URA3-pQE60 was constructed by OE-PCR using PCR products spc-amyE’, 
Cen/ARS-URA3 and pQE60 spacer-R in a three way extension reaction followed by final 
amplification using primers GFP-spc-amyE’-F and pQE60-R.  Fragments pQE60-‘amyE-
LacI, LacI-GFP, GFP-Spc-amyE’, spc-amyE’-Cen/ARS-URA3-pQE60 and NcoI/BamHI 
digested pQE60 were assembled in S. cerevisiae HZ 848 by homologous recombination 
as previously described[2] to make plasmid pBEX.  This vector is an E. coli- S. 
cerevisiae shuttle vector capable of plasmid based IPTG inducible expression of genes 
cloned between PT5 and His6 in E. coli as well as chromosomal based IPTG inducible 
expression of genes cloned between PT5 and His6 in B. subtilis when integrated into the 
neutral amyE locus.  Additionally, genes or entire pathways may be expressed under 
control of native promoters in B. subtilis when the insert is cloned between the ‘amyE  
and spc-amyE’ fragments. 
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PrISM-based screening: protein analysis and PCR.  The use of SDS-PAGE to 
survey conditions and strains was published elsewhere[1].  Bacillus isolate NE2-2 grown 
in Mueller-Hinton broth for 8 hours at 30 ºC produced the high molecular weight bands 
of Figure 4.1A.  
Mass spectrometry and data analysis:   High molecular weight protein bands were 
subjected to in-gel trypsin digestion followed by nano-capillary LC-MS/MS on a 7T 
LTQ-FT (Thermo-Fisher Scientific) equipped with an Eksigent 1D nano HPLC system 
mounted with a 100 mm X 75 μm C18 picofrit column (New Objective) and a Picoview 
500 nanospray source (New Objective).  Solvents were water with 0.1% formic acid (A) 
and acetonitrile with 0.1% formic acid (B).  Peptides were eluted with a linear gradient 
from 0% B to 65 %B over 45 minutes. MS/MS data were acquired using data-dependent 
mode; the top five peaks from the FTMS full scan (m/z 400-1800) were selected for 
fragmentation and analyzed using ion trap detection.  MS/MS data files were analyzed 
using OMSSA[3] and searched against a custom protein database containing all bacterial 
proteins and all NRPS and PKS proteins from Genbank.  Peptides identified as coming 
from NRPSs were used for degenerate primer design. 
Degenerate primer design:  Primers were designed from peptides identified as 
coming from NRPS proteins.  Peptide sequences were reverse translated using the web-
based Reverse Translate Tool (http://www.bioinformatics.org/sms2/rev_trans.html) using 
the Bacillus thuringiensis serovar kurstaki codon usage table.  Both the most likely and 
highly degenerate reverse translations were used to design primers.  None of the 
identified peptides were from the same protein therefore degenerate primers were paired 
with NRPS adenylation domain degenerate primers[4] that were modified to use the 
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Bacillus thuringiensis serovar kurstaki codon usage table.  64 PCRs were performed 
using the peptide based most likely and highly degenerate primers paired with the NRPS 
A3 and A7 degenerate primers.  One reaction gave a single, reproducible band at the 
expected size of 700 bp.  The 700 bp band was purified from the gel and sequenced using 
the primers that amplified it.  BLAST analysis of the sequence of the 700 bp band 
indicated that it coded for the N-terminal portion of an NRPS adenylation domain.  The 
sequence of the 700 bp band was used to construct probe primers for screening a fosmid 
library of bacillus isolate NE2-2 genomic DNA clones.
Fosmid library construction, screening, and cluster sequencing:  A fosmid library 
of bacillus isolate NE2-2 was prepared then screened by PCR essentially as described[5].  
The fosmid library was screened using primers NE2-2 probe-F and NE2-2 probe-R.  
Seven clones containing the probe sequence were isolated from the library screening.  
Sequencing was performed using a Roche 454 FLX-Titanium sequencer at the UIUC 
DNA Core facility on a mixture of the 7 overlapping fosmids. Sequence reads were 
assembled using the GS de novo sequencing assembler (Roche).  Automatic annotation 
was performed using RAST[6].  Targeted PCR followed by Sanger sequencing on an 
ABI 3730xl capillary system was used to close gaps and resolve ambiguities. 
 Targeted metabolite discovery and structure elucidation.  Small Molecule MS 
was performed on culture supernatant from Bacillus isolate NE2-2 grown in the same 
conditions as for protein analysis, or on semi-purified compound for direct infusion 
experiments.  For LC-MS/MS experiments a 7 or 12 T LTQ-FT (Thermo-Fisher 
Scientific) equipped with a Surveyor (Thermo-Fisher Scientific) or Agilent 1200 
autosampler and LC.  Samples were run through a 4.6 X 150 mm Jupiter C18 column 
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(Phenomenex) at 400 μL/minute using water with 0.1% formic acid (A) and acetonitrile 
with 0.1% formic acid (B) on a linear gradient from 0-100% B over 30 minutes.  Data 
were collected in a data dependent fashion, selecting the top three peaks in the FTMS full 
scan for fragmentation and detection by FTMS/MS.  For direct infusion, semi-purified or 
Zip-Tip desalted samples were dissolved in 80% acetonitrile 20% water with 0.1% 
formic acid and infused using a Nano-Mate 100 nanospray source (Advion).  Direct 
infusion data were collected manually using the LTQ-Tune function of Xcalibur 
(Thermo-Fisher Scientific). 
 Stable isotope feeding studies:  Amino acids were added (1 mM final 
concentration) as required to mannitol supplemented minimal medium (1% mannitol, 
0.1% caseamino acids, 0.1% yeast extract and M9 salts.  Single colonies were picked into 
5 mL media and grown at 30º C and 250 rpm.  1 mL samples were pulled from cultures at 
24, 36 and 48 hours, cells were removed by centrifugation then the supernatant was 
filtered through a 0.45 μm filter and stored at -20º C until analyzed.  Culture supernatants 
were analyzed by direct infusion or by LC-MS as described above. 
Heterologous  expression of koranimine gene cluster:  The full 30 kb gene cluster 
was heterologously expressed in B. subtilis under the control of the native promoters and 
integrated into the neutral amyE locus.  To construct the expression cassette, overlapping 
fosmid inserts were released from the vector by NotI/NcoI/MluI digestion.  The released 
inserts were purified from an agarose gel using standard procedures.  The released inserts 
were co-transformed into HZ 848 along with NcoI/BamHI digested and gel purified 
pBEX, essentially as previously described[2] for assembly by homologous recombination.  
Yeast clones were screened by PCR for correct inserts before the plasmid was 
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transformed into DH5α λ pir for amplification.  The plasmid was transformed into B. 
subtilis by natural transformation[7] and screened for proper insertion by PCR and assay 
for amylase activity.  B. subtilis clones grown up in the same conditions as the native 
producer were assayed by LC-MS/MS for production as described above. 
4.3 Results and Discussion 
Using mass spectrometry-based proteomics, expression of a novel NRPS gene 
cluster in the native proteome of an environmental bacillus isolate was selectively 
detected. Use of SDS-PAGE to survey 23 bacillus strains and experimental conditions 
has been described in Chapter 3. One bacillus isolate examined produced the high 
molecular weight bands of Figure 4.1A.  Direct peptide sequencing by tandem mass 
spectrometry (e.g., the spectrum of Figure 4.1B) gave the amino acid subsequences that 
were used to design PCR primers for amplification of the region between identified 
peptides and conserved core regions of NRPS adenylation domains (Figure 4.1C).  This 
amplicon was the hook into the system.  Eventual DNA sequencing of the corresponding 
gene cluster and prediction of structural elements, led to the detection of a new NRP at 
m/z 804.5 (Figure 4.2) and its structure was eventually determined to be that of 1 and 
named koranimine after the location the native host was isolated from, Koran, LA. This 7 
member cyclo-(imino)peptide motif that results from reductive chain release followed by 
head-to-tail macrocyclization was first observed in the NRPS metabolite 
nostocyclopeptide [8].   
The koranimine gene cluster was present on seven overlapping fosmids, none of 
which contained the entire gene cluster.  For this reason a new technique, DNA assembler 
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[2], was used to stitch together two overlapping fosmids and create a vector suitable for 
heterologous expression of large insert DNA in several hosts.  When the entire 30 kb 
cluster (Figure 4.3) was transplanted and heterologously expressed in B. subtilis, a time-
dependent increase of a peak at m/z 804.5 and 25 minutes was observed in the 
heterologous host, but not in the B. subtilis 168 background (Figure 4.4) confirming that 
the peak at m/z 804.5 is the product of the gene cluster.  This gene cluster was not closely 
related to other NRPS gene clusters present in Gen Bank at the time of these experiments 
(and this writing), therefore it seemed likely that the product of the gene cluster was 
unknown as well.  The structure was determined using MS/MS and MSn (Figures 4.5, 
4.6, 4.7). The proposed biosynthesis of koranimine is shown in Figure 4.8.  There are 
several notable aspects of the domain structure of the NRPSs.  First is that for KorA, 
there is a C-T di-domain that lacks a directly linked A-domain.  Second, the adenylation 
domains of KorB and KorC when subjected to standard bioinformatic analysis tools for 
A-domain substrate specificity[9] return no predictions.  Third, KorC has a very unusual 
domain structure; in addition to its cryptic A-domain, the enzyme contains a T-T-C tri-
domain with no directly linked A-domain like the C-T di-domain of KorA, but with an 
additional T-domain.  Lastly, the product was determined to be a 7 amino acid peptide, 
but the gene cluster contains only 5 amino acid activating domains.  NRPS adenylation 
domain prediction software[9] accurately predicted the first, second and seventh amino 
acids to be threonine, leucine and valine.  These are incorporated by KorA-A1, KorA-A2 
and KorD respectively.  Only after the structure of 1 was determined were we able to 
make a confident proposal for the rest of the biosynthetic pathway.  In addition to 
incorporating the second amino acid, we propose KorA-A2 incorporates the third amino 
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acid, another leucine.  This unconventional iteration of the second module would be 
enabled by the extra C-T di-domain following module 2.  Both leucine monomers are 
epimerized to the D-form by the epimerization domain in the second module (Figure 4.6).   
KorB incorporates phenylalanine and epimerizes it to the D-form (Figure 4.7).  The first 
T-domain of KorC is charged by the adenylation domain of KorD.  This long-range trans-
activation may be a rate limiting step and could explain the presence of the tandem T-
domains in the fourth module; tandem T-domains have previously been implicated in 
accelerating flux through thiotemplate systems[10-12].  Module 5 incorporates a second 
phenylalanine and epimerizes it to the D-form.  The sixth and final module, in addition to 
charging the fourth module, incorporates the seventh residue, valine.  We predict the 
terminal reductase domain performs a two-electron NAD(P)H dependent reduction of the 
C-terminal carboxylic acid to the aldehyde.  This type of product has been previously 
shown to undergo non-enzymatic macrocyclization[13] yielding the final product (1).  
We propose the type II thioesterase, KorTE to have an editing function, removing mis-
charged amino acids from the pathway and decreasing the formation of side products 
such as 3[14].  The α/β hydrolase enzyme, may also, perform an editing function, or be 
uninvolved in the biosynthesis of koranimine. 
Due to koranimine’s structural similarity to natural [15] and synthetic [16] 
chymotrypsin inhibitors, it is possible that koranimine is a protease inhibitor.  Protease 
inhibitors have found medical use due to the fact that the proteasome has a chymotrypsin-
like active site[17] and many viruses require activity of certain proteases for virulence.  
Such protease inhibitors have potential use as drugs against cancer[18], HIV[19] and 
possibly other viruses[20]. 
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The new “proteome-first” strategy indeed detects expressed gene clusters and 
directs efforts toward efficiently finding lab conditions where new natural product 
scaffolds are produced by microorganisms.  Future efforts can be scaled up and the time-
to-endpoint of new systems can be shrunk to yield a method to swoop into proteomes and 
efficiently find and correlate new natural products with their biosynthetic pathways.  
Exploring the environment of cross- and mixed-systems of microbial ecology seems now 
a straightforward path. 
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4.4 Figures and Tables 
 
Figure 4.1. PrISM-workflow for Strain NE2-2.  A.  SDS-Page gel showing high-
molecular weight protein bands analyzed by nanoLC-MS/MS (highlighted).  B.  
Representative mass spectrum for a peptide used in degenerate primer design.  C.  
Agarose gel of PCRs using peptide based degenerate primers coupled to anchoring 
adenylation domain degenerate primers, highlighted band excised and sequenced.  
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 Figure 4.2.  Structure of koranimine and related compounds 
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Figure 4.3. ORF map for koranimine gene cluster.   
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Figure 4.4.  Heterologous expression of koranimine gene cluster.  Selected ion 
chromatograms for m/z 804.500 for culture supernatant samples of indicated strain grown 
in Mueller-Hinton broth for indicated time at 30º C and 250 rpm.  There is a time-
dependent increase in the peak at 804.500 for the native producer (bacillus spp. NE2-2) 
and the heterologous host (B. subtilis 168 amyE:: koranimine cluster spc), but not the 
host background (B. subtilis 168), 
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Figure 4.5.  MSn experiments for determination of koranimine structure.  Ion structures 
inset with theoretical masses below each ion.   
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Figure 4.6.  Labeling of koranimine with D10-L-leucine followed by MSn. Ion structures 
inset with theoretical masses below each ion.  Labeling with D10 L-leucine resulted in 
only a 18 Da shift indicating loss of 2 deuterons; this is consistent with epimerization of 
the leucines from L-D.  MSn experiments localize the residues carrying the positive mass 
shift.  Deuterium labeled positions are indicated by asterisks. 
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Figure 4.7.  Labeling of koranimine with D8-15N-L-phenylalanine followed by MS2. Ion 
structures inset with theoretical masses below each ion.  Labeling with D8, 15N-
L-phenylalanine resulted in only a 16 Da shift indicating loss of 2 deuterons; this is 
consistent with epimerization of the phenylalanines from L-D.  MS2 experiments localize 
the residues carrying the positive mass shift.  Deuterium labeled positions are indicated 
by asterisks. 
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Figure 4.8. Domain structure of koranimine NRPSs and proposed biosynthetic scheme. 
A-adenylation, T-thiolation, C-condensation, E-epimerization, Red-reductase. 
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Table 4.1.  Oligonucleotides Used (Restriction Sites Underlined) 
Name Sequence 
pQE60 spacer-F ACCCACTCGTGCACCCAAC 
pQE60-‘amyE-R TTGAATCGTTTTGCAAACATACTTTTCGGGGAAATGTGCG 
pQE60-‘amyE-F CGCACATTTCCCCGAAAAGTATGTTTGCAAAACGATTCAA 
‘amyE-LacI-R GGTTGAGGCCGTTGAGCACCGATCAGACCAGTTTTTAATTTGTGTG 
‘amyE-LacI-F CACACAAATTAAAAACTGGTCTGATCGGTGCTCAACGGCCTCAACC 
LacI-Gfp-R TTTCTTAGACGTCAGGTGGCTTCCGCGTTTCCAGACTTTA 
LacI-Gfp-F TAAAGTCTGGAAACGCGGAAGCCACCTGACGTCTAAGAAA 
Gfp-spc-amyE’-R GCAGGAATTCGATAAGCTTAAGGTTTTAGCTTCCTTAGCTCCTGAAAATC 
Gfp-spc-amyE’-F GATTTTCAGGAGCTAAGGAAGCTAAAACCTTAAGCTTATCGAATTCCTGC 
Spc-amyE’-Cen-R CATGACATTAACCTATAAAAAAGGCCTCTCAATGGGGAAGAGAACCGC 
Spc-amyE’-Cen-F GCGGTTCTCTTCCCCATTGAGAGGCCTTTTTTATAGGTTAATGTCATG 
Cen-pQE60-R CGGTATTTCACACCGCATATGCTAGTAGACGAGTCCATGTGCTGG 
Cen-pQE60-F CCAGCACATGGACTCGTCTACTAGCATATGCGGTGTGAAATACCG 
pQE60-spacer-R TGCGTTATCCCCTGATTCTGT 
A-Domain A3F GCWTATSYSATKTATACDTCWGG 
A-Domain A3R CCWGTGGTATAMATSRSATAWGC 
A-Domain A7R STGRTCHCCSGTYYKGTA 
A-Domain A7F TACMRRACSGGDGAYCAS 
Peptide 1F AGATTAGCACCATTAAGTGCAGCAGAAAGA 
Peptide 1R TCTTTCTGCTGCACTTAATGGTGCTAATCT 
Peptide 1FD MGNYTDGCNCCNYTAWSHGCDGCNGARMGW 
Peptide 1RD WCKYTCNGCHGCDSWTARNGGNGCHARNCK 
Peptide2-F TTAGTAGAAGTATTACAACCAGATAGA 
Peptide2-R TCTATCTGGTTGTAATACTTCTACTAA 
Peptide 2D-F YTDGTDGARGTDYTDCARCCDGAYMGD 
Peptide 2D-R HCKRTCHGGYTGHARHACYTCHACHAR 
Peptide 3-F AGTGGTGAATGTGATTTAGC 
Peptide 3-R GCTAAATCACATTCACCACT 
Peptide 3D-F WSHGGNGARTGYGATYTDGC 
Peptide 3D-R GCHARATCTCAYTCNCCDSW 
Peptide 4-F ATGATTACAGGTATTATGGG 
Peptide 4-R CCCATAATACCTGTAATCAT 
Peptide 4D-F ATGATHACDGGNATHATGGG 
Peptide 4D-R CCCATDATNCCHGTDATCAT 
Peptide 5-F GGTTGGTTTACAAGTTTATATCC 
Peptide 5-R GGATATAAACTTGTAAACCAACC 
Peptide 5D-F GGNTGGTTTACNWSNYTDTAYCC 
Peptide 5D-R GGRTAHARNSWNGTAAACCANCC 
Peptide 6-F GATATGATTGTAGGTATTTTTGG 
Peptide 6-R CCAAAAATACCTACAATCATATC 
Peptide 6D-F GATATGATHGTNGGNATHTTTGG 
Peptide 6D-R CCAAADATNCCNACDATCATATC 
Peptide 7-F AATATGTATGGTATTACAGAAACAACAGTACATGT 
Peptide 7-R TGTACATGACAACAAAGACATTATGGTATGTATAA 
Peptide 7D-F AATATGTATGGNATYACNGARACNACNGTNCATGT 
Peptide 7D-R ACATGNACNGTNGTYTCNGTRATNCCATACATATT 
Peptide 8-F GGTTGGTTTACAAGTTTATATCC 
Peptide 8-R GGATATAAACTTGTAAACCAACC 
Peptide 8D-F GGNTGGTTTACNWSNYTDTAYCC 
Peptide 8D-R GGRATHARNSWNGTAAACCANCC 
Peptide 9-F GGTCAAAATGATATTTTAGTAGG 
Peptide 9-R CCTACTAAAATATCATTTTGACC 
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Table 4.1 (Cont).  Oligonucleotides Used (Restriction Sites Underlined) 
Name Sequence 
Peptide 9D-F GGNCAAAATGATATHYTTGTNGG 
Peptide 9D-R CCNACAARDATATCATTTTGNCC 
Peptide 10-F ATGGGTGAATTATATATTGG 
Peptide 10-R CCAATATATAATTCACCCAT 
Peptide 10D-F ATGGGNGAAYTATATATHGG 
Peptide 10D-R CCDATATATARTTCNCCCTA 
Peptide 11-F ATTGTAGAAGTAGTACAACCAGAAAGA 
Peptide 11-R TCTTTCTGGTTGTACTACTTCTACAAT 
Peptide 11D-F ATHGTNGARGTNGTNCAACCNGAAMGN 
Peptide 11D-R NCWTTCNGGTTGNACNACYTCNACDTA 
Peptide 12-F GAAAGATTTGTAGCAGATCCATTTGG 
Peptide 12-R CCAAATGGATCTGCTACAAATCTTTC 
Peptide 12D-F GAAMGNTTTGTNGCNGATCCNTTTGG 
Peptide 12D-R CCAAANGGATCNGCNACAAANCWTTC 
NE2-2-Probe-F ACTTGAGGAGACATTCGAAGAGA 
NE2-2-Probe-R CAAGCAATAGGAAATGGACGA 
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CHAPTER 5 
CONCLUSIONS 
5.1 Summary and Outlook  
Natural products are and have been the major source of drugs for the treatment of 
infections and cancer [1].  The class of natural products that is chief among the many 
types of bioactive compounds are the thiotemplate secondary metabolites, nonribosomal 
peptides and polyketides.  For this reason, much research effort has been invested in the 
discovery, synthesis and reengineering of thiotemplate systems.  Presented here are 
examples of the use of high performance mass spectrometry for the reengineering, 
discovery and biosynthetic elucidation of nonribosomal peptide synthetases.  These 
studies have been enabled through the application of directed evolution library creation 
methods [2] and cutting edge techniques for the cloning and expression of large DNA 
fragments [3]. 
High performance mass spectrometry, specifically the use of ESI-LC-FT-MS/MS 
instruments such as the 7-, 11-, and 12T-LTQ-FT systems utilized in this work has 
proven a versatile tool for interrogation of complex systems.  The sensitivity and 
selectivity of mass spectrometry allow for it to be used in high-throughput screening 
campaigns as discussed in Chapter 2.  Mass spectrometry, being a structural readout 
allows for direct and unbiased detection of small molecules present in very complex 
mixtures such as the exo-metabolomes of microorganisms.  The sensitivity afforded by 
ESI-LC-FT-MS/MS instruments allows for analysis and deconvolution of pooled samples 
as demonstrated in Chapter 2.  In addition, the versatile nature of instruments such as 
these used here, allow for a high degree of confidence in assignments of chemical 
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identity due to the unsurpassed mass accuracy of FTMS and detail in structural 
characterization by MS/MS.  Beyond the application of ESI-LC-FT-MS/MS as a lens for 
broad-view experiments such as chemical screening, this platform allows for the user to 
focus in on systems for the identification and characterization of protein, peptide and 
small molecules such as described in Chapters 3 and 4.  Coupling of ESI-LC-FT-MS/MS 
to the simple and robust protein separation technique of SDS-PAGE has allowed the 
selective detection, cloning and characterization of novel and uncharacterized NRPS gene 
clusters in organisms without knowledge of their genomic DNA sequence. Furthermore, 
the PPAnt ejection assay has proven a robust and simple tool to analyze NRPS 
enzymology for the elucidation of the biosynthesis of a novel NRPS product, koranimine.  
The full structure of koranimine was determined using MSn experiments in tandem with 
stable isotope incorporation studies.  While this feat may not be possible for all newly 
described natural products, use of MS and MSn is useful for the characterization of 
compounds that are recalcitrant to purification and analysis by other methods such as 
NMR. 
 Future work should be focused on extending the accomplishments presented here 
in regards to the reengineering and discovery of thiotemplate systems including 
developing alternative approaches to making mutant libraries such as family shuffling [4] 
in order to overcome challenges in evolving enzymes in families where little structural 
information is available.  Moving toward nano-capillary LC would provide increased 
sensitivity with concomitant decrease in sample volume required for analysis thus 
allowing for more mutants to be screened with decreased cost of media and consumables.  
Moving toward faster LC separation techniques such as ultra-high performance liquid 
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chromatography (UHPLC) could increase the throughput of the assay so that larger 
libraries could be screened with the same or decreased time cost. For discovery of novel 
thiotemplate systems using the new “proteome-first” strategy to detect expressed gene 
clusters and direct detection and characterization of new compounds focus should shift to 
more complex and difficult systems such as the genus streptomyces and the filamentous 
fungi, with an ultimate goal of being able to explore the environment of multi-organism 
assemblages such as found in marine systems [5] and the vast majority of 
microorganisms that cannot be cultivated in the laboratory [6, 7].  Such meta-proteomic 
[8] investigations would allow access to a wealth of untapped biosynthetic capacity. 
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